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ABSTRACT 
 
 Alzheimer’s disease (AD) is a neurological disorder that has been linked with 
nutrition and lifestyle choices throughout the lifespan. Although there is currently no cure, 
recent research supports dietary changes as a preventative measure for AD.  However, it is 
not clear which nutritional markers underlie the structural and functional changes in the 
brain that are seen in AD, and subsequently what aspect of the diet should be targeted in 
AD prevention and treatment.  The projects described in this dissertation provide four 
nutritional biomarkers that are associated with AD pathology: the metabolism-regulating 
enzyme autotaxin, the insulin transporter and modifier insulin-like growth factor binding 
protein 2, the antioxidant superoxide dismutase 1, and the micronutrient involved in 
methylation of proteins and lipids as well as homocysteine metabolism, vitamin B12.  These 
studies analyze neurological associations through region of interest approaches, voxel-wise 
analyses, and statistical analyses (i.e. linear mixed models, mediation models, logistic 
regression) with established cerebrospinal fluid (CSF) biomarkers of AD, cognitive test 
scores, and baseline and follow-up diagnoses.  Our findings suggest that CSF autotaxin is 
detrimental to brain health and superoxide dismutase 1 is most likely beneficial.  Insulin-like 
growth factor binding protein is suggested to be beneficial early in the AD trajectory, but 
detrimental as the disease progresses.  Lastly, our results suggest that higher serum vitamin 
B12 may be indicative of worse AD outcomes in an aged population but contrastingly better 
cognitive associations in a young population. Future studies are needed to determine 
causation as well as the impact of nutritional modifications on these biomarkers and 
subsequent brain health.   
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 GENERAL INTRODUCTION 
 
 Alzheimer’s disease (AD) is a neurodegenerative disorder that is the most common 
cause of dementia (1). The impact of AD is wide-ranging, deteriorating memory, executive 
function, spatial orientation, and activities of daily living (2).   In 2017, there were 
approximately 3.65 million individuals with AD, and this is estimated to expand to 9.3 
million by the year 2060 (3).  While AD affects less than 1% of individuals under the age of 
60, the prevalence rises to 40% in the population of individuals over the age of 85 (4).  AD 
has been associated with the accumulation of tau tangles and amyloid plaques in the brain, 
but the underlying causes of these protein changes in the brain is yet to be determined (1).   
Nutrition and is thought to be involved as high dietary intake of antioxidants and 
omega-3 fatty acids and moderate alcohol consumption are linked with decreased risk for 
AD (4).  On the other hand, obesity in the midlife is associated with a 2.4 increase in odds for 
developing AD (5).  Further, midlife diabetes is associated with a 1.42 increased odds ratio 
for AD (6).  Compellingly, mice that were fed components that make up the typical western 
diet (high fat and saturated fat, elevated simple carbohydrates and low omega-3 and 
omega-6 fatty acids) led to both a loss of hippocampal neuronal cells and formation of 
reactive astrocytes in the hippocampus, which is greatly affected by AD (7).  The potential 
mechanisms behind these relationships, which will be discussed further in this dissertation, 
are thought to involve inflammation, oxidative stress, and dysregulated metabolism within 
the brain.   
 The determination of clinical biomarkers of AD, or its precursor mild cognitive 
impairment (MCI), can improve diagnostic accuracy and provide potential new drug targets 
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for improving symptoms, slowing progression, and bring the scientific community closer to 
more effective treatments and a cure (8).  Besides tau and amyloid, current prominent 
biomarkers for AD include neurofilament light protein, neuron-specific enolase, visinin-like 
protein 1, heart fatty acid binding protein, and the glial activation marker YKL-40, however a 
current issue is lack of autopsy confirmation of biomarkers (9).  Because of the evidence 
surrounding the role of nutrition in AD, nutrition-related biomarkers may track 
neurodegeneration and also provide a modifiable target through dietary changes.     
Dissertation Organization 
 This dissertation is made up of eight chapters with a general introduction, a 
literature review, five manuscript-style chapters, and a general conclusion.  The first 
manuscript chapter titled “Autotaxin is Related to Metabolic Dysfunction and Predicts 
Alzheimer’s Disease Outcomes” explores the role of the insulin-resistance-related 
biomarker, autotaxin, in AD and was published in the Journal of Alzheimer’s Disease.  
Continuing the theme of insulin resistance, the next chapter is titled “Peripheral versus 
Central Index of Metabolic Dysfunction and Associations with Clinical and Pathological 
Outcomes in Alzheimer’s Disease” which assesses insulin-like growth factor binding protein 
2 (IGFBP-2) as a marker of changes in grey matter, cerebral glucose metabolism, and 
cognitive functions.  This manuscript was also published in the Journal of Alzheimer’s 
Disease.  The third manuscript chapter centers on reactive oxygen species and how the 
antioxidant superoxide dismutase (SOD) may track AD-related changes as well as its 
relationship with tau.  This manuscript is titled “Is CSF SOD1 a Biomarker of Tau but not 
Amyloid Induced Neurodegeneration in Alzheimer’s Disease?” and is currently in press with 
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the journal Antioxidants & Redox Signaling.  Transitioning to vitamin B12, the fourth 
manuscript chapter examines the role of vitamin B12 in grey matter and brain metabolism 
outcomes and is titled “Serum Vitamin B12, and Related Cubilin Genotypes, Predict Neural 
Outcomes across the AD Spectrum” and is currently in revision with The British Journal of 
Nutrition.  The last manuscript-style chapter consists of preliminary results regarding 
vitamin B12 and cognition from the study Obesity, Signal Imaging, and Reactions at Iowa 
State (OSIRIS) and is titled “Serum Vitamin B12 is Related to Improved Executive Function in 
Young Adults”.  This manuscript will be prepared for submission to a scientific journal after 
further data from the study becomes available for additional analyses. 
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 LITERATURE REVIEW 
 
Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a progressive, degenerative disorder characterized by 
loss of brain cells, or neurons, in individuals typically over the age of 65 (1).  This leads to the 
loss of memory, disorientation, psychiatric symptoms, decline of activities of daily living, 
and confusion (2).  Small changes are thought to begin in the brain 20 years before a patient 
may notice symptoms (1).  Alterations in two types of proteins are thought to play a role in 
the pathogenesis of AD: beta amyloid plaques and tau tangles (3).  These plaques and 
tangles can prevent communication between neurons, as well as deteriorate their structure 
and function(4).  Approximately one-third of older adults show brain changes related to AD 
without any presenting symptoms, suggesting that there is still a disconnect between 
diagnostic criteria and symptoms and a need for further biomarkers of the disease (5).   An 
absolute diagnosis of AD can only be made at autopsy, however criteria are set for probable 
clinical diagnoses using neuropsychological examinations, reports from the patient and an 
informant about activities of daily living, and a complete history of symptoms (4).  Currently, 
AD is clinically diagnosed in the United States using the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer's Disease and Related 
Disorders Association (NINCDS-ADRDA) (4).  Mild Cognitive Impairment, or MCI, is the 
precursor to AD.  Patients with MCI show lower scores on one or greater cognitive domain, 
when assessed objectively (6).  However, these patients are still able to complete basic 
activities of daily living, such as dressing, bathing, or hygiene (7).   
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Areas of the brain that are most susceptible to AD-related degeneration include: the 
medial temporal lobe, the lateral temporal and parietal areas, the cingulate cortex, and the 
frontal lobe (8).  The medial temporal lobe is made up of the hippocampus, the entorhinal 
cortex, and the parahippocampal gyrus (9).  These areas are important for episodic memory 
(events), associative memory (associating two memories together), semantic memory 
(general facts), and spatial memory (9).  The lateral temporal cortex plays important roles in 
auditory memory, reading and naming visual stimuli (10).  The lateral parietal cortex is also 
thought to be involved in memory retrieval (11) and the cingulate cortex is implicated in 
emotion, executive function, spatial orientation, and also has connections to the 
parahippocampal gyrus and is thought to be involved in memory (12).  Lastly, the frontal lobe 
is engaged in attention, executive function, decision making, language, personality, affect, 
and mood (13). 
Cognitively, patients with AD are known to experience numerous deficits.  
Autobiographical memory degradation is a hallmark symptom of AD, where patients are 
first unable to form new memories, and then unable to remember memories from the past 
(14).  Executive function, which is involved in planning, controlling behavior, and inhibition, is 
diminished in AD (15).  Further, spatial disorientation is common in patients with AD and 
individuals with MCI often have difficulty with navigation (16).  Depression, irritability, and 
other mood disturbances are also common (17). 
AD is currently the 6th leading cause of death in the United States.  It is estimated 
that there are currently 5.8 million Americans living with AD (1).   Medical and other related 
expenditures for Alzheimer’s disease were responsible for a cost of $290 billion in the 
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United States in 2017 (1).  Close to two-thirds of individuals with Alzheimer’s disease are 
women, and African-Americans are twice as likely to be diagnosed with Alzheimer’s disease 
as Caucasian individuals(1). 
Apolipoprotein e4 or APOE e4 is considered a genetic risk factor that contributes to 
AD.  Apolipoproteins serve to transport cholesterol and phospholipids (18).  Three isoforms 
of APOE exist: APOE e2, APOE e3 and APOE e4, stemming from amino acid changes at 
residues 112 and 158 of the APOE gene (19).  APOE e4 is less stable than the more common 
APOE e3, and more likely to be degraded by astrocytes, which maintain the blood brain 
barrier and act as neuronal-repair cells (18).  Additionally, APOE e4 has a higher affinity for 
binding to VLDL in the blood, compared to APOE e2 and APOE e3, leading to an increase in 
LDL in the blood (19).  Importantly, apolipoproteins are postulated to be involved in beta 
amyloid clearance from the brain, so it can be asserted that individuals who have at least 
one copy of APOE e4 are less able to efficiently clear beta amyloid plaques (18).  It is currently 
estimated that one copy of the APOE e4 allele is associated with a 3 times increased risk for 
AD, while possessing two copies is associated with a 12-fold increased risk for AD (20).  
Conversely, the APOE e2 allele is considered protective against developing AD, where 
having at least one e2 allele led to a 0.08 odds ratio for AD compared to having at least one 
e3 allele with an odds ratio of 0.16 (21).  Additional gene mutations are associated with the 
development of AD including: amyloid precursor protein (APP), presenilin 1 (PSEN1), and 
presenilin 2 (PSEN2), clusterin (CLU), Triggering Receptor Expressed on Myeloid Cells 2 
(TREM2) and Phosphatidylinositol-Binding Clathrin Assembly Protein (PICALM) (20; 22). 
 8 
Many theories have been proposed in determining the root cause of AD.  Although it 
is not known conclusively why amyloid amasses in those with AD, it is thought to be related 
to dysfunction of the APOE gene and cholesterol metabolism (23).  Cholesterol-rich domains 
in the lipid bilayer of cell membranes are thought to be involved in the production of 
amyloid precursor protein; both serum total cholesterol and LDL cholesterol have been 
correlated with beta amyloid plaques in the brain (24; 25).   As amyloid plaques accumulate, 
an inflammatory cascade is put in motion, where the activated glia cells that surround 
neurons, astrocytes, begin releasing cytokines in an attempt to control the offending 
plaques (22).   In excess, these cytokines can lead to chronic neuroinflammation and 
neurodegeneration (26).  In addition, glial fibrillary acidic protein is released from astroctyes 
which corresponds with the uptake of the excitatory neurotransmitter glutamate, thus 
sequestering glutamate from the neurons to prevent hyperexcitation of the neurons and 
apoptosis (26; 27).  As glutamate is taken up into the astrocytes, glutamate is converted to 
glutamine, which has been found in higher levels of AD patients (26; 28; 29).  These astrocytes 
begin to hypertrophy and release higher amounts of the inhibitory neurotransmitter, GABA 
(30).  It can be hypothesized that these changes lead to the dysregulation of 
neurotransmitters that is seen in AD (22).  Another hypothesis is that cholinergic neurons, 
neurons that use acetylcholine as signaling molecules, dysfunction (31).  Neuroinflammation 
has been shown to lead to a decrease in nerve growth factor, which binds to receptors on 
cholinergic neurons and is thought to be necessary for their survival, especially in the 
forebrain (31).  Transitioning to tau, tau is a microtubule protein that is found in neurons and 
is regulated through post-translational phosphorylation (32).  Mutations in the gene that 
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encodes for tau, MAPT, have been linked with neurodegeneration (23).  Abnormal 
phosphorylation of tau can lead to aggregations of the protein which can in-turn disrupt the 
transport of neuron to neuron signals via axons (23).  
Despite the increased research focus and federal funding, there is currently no cure 
for AD, and clinical treatments focus on symptom management (33).  Drugs that target 
amyloid production by b- and g- secretase inhibitors failed to meet effectiveness standards 
or were deemed unsafe for human consumption (33).  Immunotherapy has also been 
investigated as a potential target for amyloid proteins but a major clinical trial was 
discontinued due to 6% of subjects in the treatment group developing meningoencephaltis 
(34).  The drug memantine is a NMDA receptor agonist which is thought to decrease 
sustained blockage of NMDA receptors that is seen in AD (35).  Memantine is currently 
approved for the treatment of AD, however only some studies have found utility of the 
drug, in the form of small improvements in memory or activities of daily living (35).  
Cholinesterase inhibitors are also prescribed to individuals with AD, which decrease the 
breakdown of acetylcholine in the synaptic cleft, thereby increasing neuronal 
communication, which leads to small increases in global cognition and activities of daily 
living (36).  Interestingly, there is potential for rheumatoid arthritis drugs that block the 
production of the protein tumor necrosis factor alpha (TNFa) as an AD prevention or 
treatment.  Though the drug is too large to cross the blood brain barrier, its use has been 
associated with decreased risk for AD, highlighting the importance of controlling peripheral 
inflammation (37). 
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Obesity and Insulin Resistance 
 
Obesity is linked with heart disease, diabetes, cancer, joint ailments, and many other 
chronic diseases (38).   According to the Centers for Disease Control and Prevention, more 
than one third of adults in the United States have obesity (39).  Additionally, it is estimated 
that obesity was responsible for $147 billion dollars in medical costs in the U.S. in 2008 (39).  
Some minority groups are disproportionately affected by obesity, with Hispanic having the 
highest rates (47.0%) followed by non-Hispanic blacks (46.8%) (39).  
 Strong correlations have been shown between obesity and insulin resistance (IR), 
which is defined as the progressive inability for insulin to bind to its receptor (40).  This is 
thought to be due to increases in inflammatory factors, as well as the release of non-
esterified fatty acids (NEFAs) from adipose tissue, creating a competition with glucose for 
energy substrates for cells and a down-regulation of certain glycolysis enzymes (41).   The 
raised levels of circulating glucose and NEFAs are thought to cause the pancreatic beta cells 
to increase in mass and secrete higher levels of insulin, leading to an increased level of 
insulin required for cells to uptake glucose (41).  In the Nurses’ Health Study cohort, BMI was 
correlated with a diagnosis of diabetes, and women with a BMI of 25-26.9 had a five times 
increased risk for diabetes compared to women with a BMI of under 22 (42).  In a large 
clinical trial with individuals with prediabetes and a BMI of 24 or greater, individuals who 
received an intensive weight-loss lifestyle intervention lost an average of 5.6 kg and had a 
58% lower risk of being diagnosed with diabetes compared to a placebo group and a 27% 
reduced risk of diabetes compared to a group on metformin therapy (43).  Even individuals 
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with obesity that were considered metabolically healthy had four times the risk of being 
diagnosed with type 2 diabetes compared to healthy lean individuals (44).   
It has been estimated that by the year 2030, there will be 439 million individuals 
world-wide with diabetes, which is a 54% increase from the year 2010 (45).  Type 1 diabetes 
is a genetic auto-immune disease where beta cells of the pancreas are attacked, and it 
affects about 5-10% of those with diabetes.  About 90% of individuals with diabetes have 
type 2 diabetes, which is related to IR (46).   Risk factors for type 2 diabetes include: diets low 
in fiber, high in glycemic index foods, high in trans-fat and saturated fat; low physical 
activity; smoking; elevated levels of alcohol intake; and increased levels of total adiposity 
(47). 
Many studies have linked obesity and IR with wide-ranging inflammation (48; 49).  
Human capillary endothelial cells treated with adipocyte cell medium showed increased 
adhesion of monocytes (a type of white blood cell which can indicate inflammation) 
compared to endothelial cells grown in a control medium (50).   Additionally, these authors 
found a positive correlation between the number of macrophages that were present in 
human adipose tissue and BMI (50).  Other studies have shown increased markers of 
inflammation in adipose tissue from obese individuals, such as tumor necrosis factor- alpha, 
interleukin-6, and monocyte chemotactic protein-1 (51).   Further, adipose tissue sampled 
from lean and obese individuals showed significantly higher expression of Cd68, a low-
density lipoprotein that is expressed on macrophages and monocytes, in adipose tissue 
sampled from obese participants, compared to lean (51).  Lastly, the same study showed that 
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there was a positive correlation between average adipocyte cross-sectional area and Cd68 
levels, indicating that enlarged adipocytes are inflammatory to the body (51).    
Obesity and the Brain 
 
Obesity is associated with decreased grey matter and metabolic function in the brain 
(52; 53).  Further, obesity is associated with decreased blood flow to the brain, which 
correlates with brain tissue degeneration (54).  Rats fed a high fat diet for 16 weeks showed 
higher levels of the inflammatory marker TNFa in the hypothalamus compared to rats fed a 
control diet (55).  In the observational UK Biobank study, total body fat was associated with 
less grey matter in the thalamus, caudate nucleus, putamen, globus pallidus, hippocampus, 
amygdala, and nucleus accumbens for male participants but only related to less grey matter 
in the globus pallidus in women, which the authors postulated may have been due to a 
protective effect of estrogen (56).  In contrast, higher total body fat was linked to increased 
white mater integrity in both male and female participants (56). 
However, the relationship between obesity and brain degeneration may be related 
to obesity comorbidities.  One study showed that BMI was associated with cognitive tests 
related to attention and verbal fluency, but memory, processing speed, and executive 
function were only correlated with obesity-related comorbidities such as diabetes, CPAP 
usage, and apnea (57).  
As an alternative or concurrent theory, the inflammation associated with obesity 
may determine neuronal degeneration.  Obesity is associated with an increased production 
of cytokines, which have the ability to cross the blood brain barrier (58).  High levels of C-
reactive protein, an inflammation marker, have been associated with increased white 
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matter damage in individuals free of dementia (59).   In participants ranging from age 35 to 
85 years of age from the Framingham Heart Study, there was an overall negative effect of 
nine blood-based inflammatory markers on total brain volume adjusted for head size (60).   
Further, for middle-aged to aged participants from the Rotterdam Study, participants in the 
highest quartile for baseline plasma inflammatory proteins compared to the lowest quartile 
had a 2.92 increased odds ratio for developing dementia (61).  Providing a potential cause 
and effect, a high fat diet induced model of obesity in rodents led to an increased level of 
CD68+ activated microglia in the hippocampus of aged mice compared to mice fed a control 
diet (48). 
Insulin Resistance and the Brain 
 
 Normal aging results in progressive IR, due to increased fat mass and decreased lean 
muscle mass (62).  Insulin resistance in cognitively normal participants in late middle age led 
to lower global glucose metabolism in the brain as well as decreased immediate and 
delayed memory (52).  Additionally, higher IR was associated with decreased cerebral glucose 
metabolic rate and worse memory scores in cognitively normal adults with pre-diabetes or 
type 2 diabetes (63).  Further, diabetes was significantly associated with worse cognitive 
performance and attention deficit in young adults without dementia (64). Last, a lower 
insulin sensitivity index in rhesus monkeys was associated with less medial temporal lobe 
(MTL) and prefrontal cortex (PFC) gray matter, which mediated worse executive function 
performance (65).   
Alzheimer’s disease (AD) has been linked with dysregulation of the insulin-signaling 
pathway (66).  This manifests in structural and functional deficits of the brain.  The Mayo 
 14 
Clinic Study of Aging showed that in a cohort of late-aged adults, midlife diabetes was 
associated with decreased executive function scores, decreased global cognition, and a 
higher odds ratio for being diagnosed with MCI (7).  Individuals with type 2 diabetes in the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) showed decreased [18F]-
Fluorodeoxyglucose (FDG)-PET uptake on a whole-brain level compared to individuals 
without a diagnosis of type 2 diabetes.  In addition, in a subset of individuals with MCI, a 
concurrent diagnosis of diabetes was related to less FDG uptake in the frontal lobe, sensory 
motor cortex, and striatum compared to individuals who had MCI but no type 2 diabetes 
diagnosis (67).      
Several studies have made convincing arguments that glycemic control determines 
these pathological changes.  In the Mayo Clinic Study of Aging, a diagnosis of diabetes was 
associated with incidence of subcortical infarctions, and individuals with diabetes that were 
receiving pharmacologic treatment displayed lower levels of subcortical infarctions 
compared to participants with diabetes that were not receiving treatment, suggesting that 
uncontrolled hyperglycemia and damage to the brain vasculature may be linked (68). To 
further this notion, use of the anti-diabetes medication pioglitazone, which regulates the 
control of insulin via gene transcription, in individuals with non-insulin dependent diabetes 
was matched with decreased risk for dementia compared to individuals who did not take 
the drug (69).  Interestingly, hemoglobin A1C levels mediated the relationship between 
duration of type 2 diabetes and worse executive function scores, where individuals with 
higher hemoglobin AIC had worse executive function scores (70).   
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Interventions aimed at improving insulin sensitivity may slow the cognitive decline 
seen in MCI.  Moderate calorie restriction has been shown to increase insulin sensitivity and 
decrease hemoglobin A1C and fasting blood glucose (71).  Anson and colleagues found that 
on average, mice that were only given access to food every other day and mice that were 
given ad libitum food access consumed the same amount of food over a 48-hour period. 
However, the researchers found that the intermittent CR mice had significantly lower 
fasting serum insulin and glucose levels, compared to ad libitum food access mice (100 
mg/dL glucose vs. 150 mg/dL and 1,100 pg/mL insulin vs. 3,400 pg/mL) (72).  The authors 
postulated that the mice were better able to metabolically adapt to smaller periods of high 
intake than constant intake. Further, rats that were fed a CR diet showed decreased 
mitochondria damage as they aged, compared to control fed rats (73).  A 500-calorie deficit a 
day or minimum 1200 kcal/day diet in subjects with MCI and obesity led to weight loss, with 
higher weight loss leading to improved verbal memory, language, and executive function 
(74).  In a cohort of bariatric surgery patients, as HOMA-IR levels decreased following the 
surgery, cognition scores improved (75).  In addition, daily intranasal (delivered directly to 
the central nervous system) insulin therapy for four months in individuals with MCI or AD 
led to significantly improved delayed recall and caregiver rated activities of daily living (76).  
Aerobic exercise is capable of increasing the effectiveness of the insulin-dependent GLUT4 
glucose transporter (77).   The Alzheimer’s Disease Exercise Program Trial showed that 
individuals with MCI who were randomized to engage in 150 minutes of aerobic physical 
activity per week showed an increase in functional abilities but no statistical differences 
from control in the areas of memory and executive function (78).   
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The Insulin Signaling System and the Brain 
 
The insulin signaling system is made up of insulin, insulin-like growth factors (IGF) 1 
and 2, insulin-like growth factor binding proteins (IGFBP) and insulin receptors (79).   IGF 
system-wide functions include: DNA synthesis, regulating cell proliferation, controlling cell 
death, and uptake of glucose and amino acids into the cells (80; 81).  IR and T2D are preceded 
by dysregulation of insulin-like growth factor-1 (IGF-1) (82).    
 Insulin crosses the blood brain barrier and can increase the transport of certain 
amino acids and the satiety hormone leptin across the blood brain barrier (83).  Even though 
the brain was assumed to be insulin-independent due to its superseding utilization of 
glucose, insulin receptors are located in the neurons and glia, and are now known to be 
important for brain glucose metabolism (84).  The hypothalamus, a region important for body 
homeostasis, contains GLUT 4 glucose transporters, which are insulin-dependent.  In 
addition, the hippocampus and cerebellum also contain GLUT 4, indicating their 
responsiveness to insulin (83).  However, the role of insulin in the brain may be for purposes 
outside of glucose uptake, as all areas of the brain contain GLUT 1 and GLUT 3, which are 
insulin-independent (85).  To support this, insulin binding has been associated with 
regulatory roles in the brain such as neurotransmitter uptake and degradation and altering 
the sensitivity of post-synaptic neurons (86). 
Insulin receptor dysregulation is thought to play a role in AD.  When beta amyloid 
was introduced to hippocampal neurons, insulin receptors redistributed on the neurons, 
where the neurons no longer showed insulin receptors on the dendrites of the neurons, 
indicating that amyloid formation and insulin receptor dysfunction may be bidirectional (87).  
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Post-mortem brain slices from individuals with frontotemporal dementia, which is also 
marked by grey matter loss and accumulation of tau, showed decreased immunoreactivity 
to IGF-1 in the frontal lobe compared to control brain slices (88).  With all of these points 
considered, it is of great interest to determine if pharmaceutical or diet/lifestyle 
interventions may exist to maintain proper insulin signaling in the brain especially in the 
setting of system-wise insulin resistance. 
Reactive Oxygen Species 
 
Reactive oxygen species are reactive superoxide anions produced during normal 
function of the electron transport chain in the mitochondria, as well as a result of ionizing 
radiation, activation of neutrophils and macrophages, lipid peroxidation, air pollutants, and 
glycation glycoxidation products (89; 90).  These reactive oxygen species can build up over 
time and cause damage to protein, lipids, and nucleic acids (90).  Additionally, free radicals 
can oxidize low density lipoprotein (LDL) cholesterol, which can lead to atherosclerosis of 
the arteries and endothelial dysfunction (91).  On the other hand, reactive oxygen species are 
beneficial and necessary in small amounts, by way of signal transduction, regulation of 
biological processes, and defense against pathogens (92). 
Nutrition and Reactive Oxygen Species 
 
Nutrition plays an important role in reactive oxygen species quenching, as vitamin C, 
vitamin E, glutathione and beta carotene are all able to be oxidized in place of physiological 
substrates (93).  Additionally, the enzymes superoxide dismutase (SOD), glutathione 
peroxidase, and catalase are produced by the body in order to control free radical 
concentration and limit damage (93).  These enzymes can also be influenced by diet.  One 
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study showed a positive association between leafy green and cruciferous vegetable intake 
and erythrocyte SOD activity and a negative association between flour and grain products 
and erythrocyte SOD activity (94).  The authors also found a positive association between 
breakfast cereal consumption and glutathione peroxidase concentrations and a negative 
association between milk, vegetable dishes, beans and lentils and glutathione peroxidase 
(94).  Additionally, a study which dosed 13 aged men with 0.1 g/kg body weight garlic daily 
for one month showed a statistically significant increase in erythrocyte SOD compared to 
baseline (95). 
Antioxidant System, Aging, and AD 
 
Over time, the antioxidant system in the body becomes less efficient, which is 
evidenced by the production of less active antioxidant enzymes (90).  In addition, premature 
aging has been associated with increased oxidative damage, especially in mitochondria 
protein (96). A statistically-significant increased level of oxidative damage to proteins has 
been shown in fibroblast cells from donors over the age of 60 compared to individuals less 
than 60 years of age (97).  
Reactive oxygen species are thought to play a role in the onset and progression of 
AD.  Increased levels of isoprostanes, markers of lipid peroxidation, were shown to be 
significantly higher in the urine, plasma and CSF of AD and MCI participants, compared to 
controls (98).   Additionally, a strong link between beta amyloid plaques and oxidative 
damage has been shown (99).  Further, addition of beta amyloid to rat embryonic 
hippocampal cell cultures causes an increase in ornithine decarboxylase, indicative of free 
radical damage, and cell death, but this is mitigated by the addition vitamin E to those 
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cultures (100). It is unclear if the oxidative damage seen in AD is a result of the disease 
process or causative of neurological decline. 
Despite the evidence of oxidative damage in AD, supplementation with single 
antioxidants has not been shown to be beneficial with respect to brain health (101).  
However, when antioxidant intake was assessed based on dietary recall, there was an 
inverse relationship between vitamin E intake and risk for dementia at a mean follow-up 
time of 9.6 years (102).  Additionally, consumption of omega-3 rich oils and daily 
consumption of fruits and vegetables was related to a decreased risk for dementia at four-
year follow-up in individuals 65 years of age or older, indicating a protective effect of 
antioxidant-rich foods (103).  
Superoxide Dismutase (SOD) 
 
SOD is an antioxidant enzyme that catalyzes the oxidation-reduction reaction of the 
superoxide anion (O2•−) into oxygen (O2) and hydrogen peroxide (H2O2) (104). SOD consists of 
three isoenzymes: copper/zinc SOD, or SOD1, localized predominantly to the cytosol; 
manganese SOD, or SOD2, within mitochondria; and extracellular SOD, or SOD3. Altered 
levels of SOD can cause excess ROS in cells, leading to altered intracellular and 
mitochondrial metabolism, as well as DNA and vascular damage (105; 106; 107; 108). 
Interestingly, synthetic SOD injected into mice shows that increased SOD levels may 
reverse cognitive dysfunction induced by oxidative stress and aging (109). However, SOD1 
overexpression in the hippocampus of middle-aged rats silences N-methyl-D-aspartate 
receptor channel activity, a molecular mechanism of synaptic plasticity underlying learning, 
which coincides with difficulty in learning a cue discrimination task and oxidative stress in 
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hippocampal tissue (110). These effects seem specific to SOD1, because overexpression of 
SOD2 has no effects on synaptic plasticity (111), and partial null mutations of SOD2 lead 
predominantly to increased cerebrovascular damage but less Aβ in amyloid precursor 
protein (APP) mice (112). These results suggest that SOD1 specifically is integral to synaptic 
plasticity and memory formation. 
SOD and AD 
 
By extension, SOD1 has been examined in AD for its role in preserving neural 
integrity and memory performance. SOD affects mitochondrial integrity and free radical 
levels (113), and these free radicals are in turn linked to beta-amyloid (Aβ) associated 
neurodegenerative etiopathogenesis (114). Overexpression of APP and SOD1 in transgenic 
mice shows pronounced atrophy in hippocampus and cortical regions, whereas SOD1 alone 
induces cortical atrophy, suggesting AD-like changes. It is not surprising that increased SOD1 
levels are seen in the pyramidal neurons of AD patients compared to controls (115). When 
examining single nucleotide polymorphisms (SNPs) among SOD1 and SOD3 genes for AD 
patients and controls, the only “hit” found was for SOD1 rs2070424 minor G allele carriers 
who showed a 50% reduction in AD risk (116). For hippocampal cells of AD patients and 
related transgenic models, SOD1 overexpression downregulates Aβ-induced reductions of 
the non- versus oxidized glutathione ratio, a marker of oxidative stress (117), whereas SOD1-
deficient Tg2576 mice show increased Aβ plaque formation, neuroinflammation, and 
memory decline (118). Further, co-expression of SOD1 in APP transgenic mice blocks 
endothelial dysfunction that gives rise to hypoperfusion often seen in AD (119). Finally, 
lifestyle interventions may affect SOD1 and neurodegenerative processes, where exercise 
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among transgenic tauopathy mice induces SOD1 expression that coincides with markedly 
lower phosphorylated tau levels in CA3 of hippocampus (120).  
Despite the critical role of SOD1 in maintaining synaptic plasticity and memory, as 
well as its dysregulation in AD and AD transgenic models, SOD1 levels have not been fully 
studied as a biomarker of AD onset and progression.  In a cohort of Malayasian older adults, 
participants with cognitive decline had significantly lower levels of plasma SOD compared to 
healthy controls (121).   Previously, baseline SOD-1 among Down’s syndrome patients, who 
almost universally develop AD neuropathology, has not predicted cross-sectional memory 
performance (122) but does strongly track longitudinal decline (123). 
 
Vitamin B12 
 
 Vitamin B12, also known as cobalamin, is a water-soluble vitamin that is necessary 
for red blood cell formation and DNA synthesis and contributes to the production of myelin 
the central nervous system (124).  The vast majority of vitamin B12-rich foods are of animal 
origin, causing difficulties for vegans and even lacto-ovo-vegetarians to meet their vitamin 
B12 needs (125).  The few plant sources of vitamin B12 include: tempeh (due to 
fermentation), certain types of mushrooms, tea leaves, and edible algae (126).  Vitamin B12 
cannot be produced my humans or other animals, as only some bacteria and archaea have 
the ability to produce the micronutrient (127).  Although vitamin B12 is produced by gut 
microbiota, it cannot be absorbed by the host as its production is past the absorption site in 
the ileum (128).  See Table 2.2 for a listing of common food sources of vitamin B12. 
 When vitamin B12 is consumed, it binds to transcobalamin I, which resides in the 
saliva (125).  Once the bound vitamin B12 reaches the stomach, stomach acid separates it 
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from transcobalamin I, where it binds to intrinsic factor, which is produced in the parietal 
cells of the stomach.  The bound intrinsic factor and vitamin B12 travel through the small 
intestine to the ileum, where vitamin B12 is absorbed via the protein cubilin into the ileum 
enterocyte (125).  Vitamin B12 is transported through the blood via transcobalamin II or via 
another carrier, haptocorrin to target tissues (125).    Vitamin B12 travels to the kidney for 
control of the amount of circulating vitamin B12 via the protein megalin and to the liver to 
act as a cofactor in vitamin B12-dependent reactions (129). 
  
Table 2.1 Recommended Dietary Allowances for Vitamin B12 
 
Age Male Female Pregnancy Lactation 
0-6 months* 0.4 mcg 0.4 mcg   
7-12 months* 0.5 mcg 0.5 mcg   
1-3 years 0.9 mcg 0.9 mcg   
4-8 years 1.2 mcg 1.2 mcg   
9-13 years 1.8 mcg 1.8 mcg   
14+ years 2.4 mcg 2.4 mcg 2.6 mcg 2.8 mcg 
 
Adapted from (124) 
 
Table 2.2 Food Sources of Vitamin B12 
 
Food Mcg per serving Percent DV 
Clams, cooked, 3 oz 84.1 1,402% 
Nutritional yeast, fortified with 100% DV B12, 1 
serving 
6.0 100% 
Salmon, sockeye, cooked, 3 oz 4.8 80% 
Breakfast cereals, fortified with 25% DV B12, 1 serving 1.5 25% 
Beef, top sirloin, broiled, 3 oz 1.4 23% 
Milk, low-fat, 1 cup 1.2 18% 
Egg, whole, hard boiled, 1 large 0.6 10% 
Chicken breast, roasted 3 oz 0.3 5% 
*Based on a daily value of 6.0 mcg 
Adapted from (124) 
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Vitamin B12 Deficiency  
 
 Vitamin B12 deficiency is defined as serum vitamin B12 values below approximately 
170-250 pg/mL (124).  However, methylmalonic acid levels above 0.4 µmol/L may be a more 
sensitive indicator, as vitamin B12 is required for methylmalonic acid to be converted to 
succinyl-CoA for metabolism of odd-chain fatty acids (124).  Symptoms of vitamin B12 
deficiency include weakness, fatigue, trouble concentrating, constipation and depression 
(124).  Vitamin B12 deficiency causes megaloblastic anemia and is more common in the aged 
population due to decreased intrinsic factor production (130).  In a more rare but serious 
manner, pernicious anemia can lead to serious vitamin B12 deficiency due to a deficiency of 
intrinsic factor (131).  B12 deficiency is particularly prevalent in India and parts of Africa due 
to lower consumption of animal products (131).  Additionally, gastric bypass surgeries lead to 
vitamin B12 malabsorption due to loss of much of the stomach and subsequent parietal 
cells. Intramuscular or sublingual vitamin B12 is routinely prescribed to gastric bypass 
patients in order to avoid vitamin b12 deficiency (132).  Chronic use of proton pump 
inhibitors for management of acid reflux has been linked with vitamin B12 deficiency, 
presumably due to the suppression of stomach acid, which is necessary to release the 
consumed vitamin B12 from its food matrix (133).  Additionally, use of the diabetes 
medication metformin can significantly decrease serum vitamin B12 levels, most likely due 
to changes in calcium cations, which are necessary for intrinsic factor to bind to vitamin B12 
for absorption into the ileum enterocyte (134).   
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One Carbon Metabolism 
 
 In the methionine homocysteine cycle, methionine can be converted to s-adenosyl-
methionine or SAM (135).  SAM has the ability to methylate DNA, RNA, and proteins, which 
can regulate gene expression (135).  After SAM donates a methyl group, s-adenosyl-
homocysteine is generated, which is then converted to adenine and homocysteine (136).  
Homocysteine can then be converted to cystathione with the addition of serine via the 
transulfuration pathway or regenerated to methionine via methionine synthase, which 
requires vitamin B12 as a cofactor and 5-methyltetrahydrofolate as a methyl group donor 
(137).  An additional remethylation pathway exists, where choline is oxidized to betaine and 
donates a methyl group, regenerating methionine (137).   
 
 
Figure 2.1 Homocysteine-Methionine Cycle 
 
Adapted from (137) 
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DMG= dimethylglycine; SAM= S-adenosylmethionine; SAH= S-adenosylhomocysteine; MS= 
methionine synthase; THF= tetrahydrofolate; CBS=cystathionine β-synthase; CGL= 
cystathionine γ-lyase; BHMT=betaine-homocysteine S-methyltransferase; MTs= 
methyltransferases; MTHFR=5,10-methylene-THF reductase; SHMT=serine 
hydroxymethyltransferase 
Vitamin B12 and Cognition 
 Because of vitamin B12’s role in the nervous system, there has long been interest in 
how vitamin B12 may affect cognition. Compared to the older population, there has been 
limited research in the younger adult population with regard to vitamin B12 and cognitive 
outcomes.  Qin and colleagues assessed vitamin B12 in a cohort of young adult females 
three times over 25 years.  At the end of 25 years, cognitive testing showed that individuals 
who consumed in the top quintile of vitamin B12 compared to their peers showed 
significantly better scores in the digit symbol substitution test, which assesses executive 
function (138).  By way of other positive associations, a cohort of young women showed a 
positive correlation between usual dietary vitamin B12 and vitamin B6 intake and 
recognition memory in the Rey Auditory Verbal Learning Test (139).   
Studies reporting the impact of vitamin B12 on cognition in older adults are more 
frequent.  In a study of 1,000 community dwelling adults aged 75 and older, individuals in 
the lowest quartile for vitamin B12 status scored worse on the Mini Mental State 
Examination, compared to the top quartile (140).   A large study with Chicago residents over 
the age of 65 showed a statistically significant negative correlation between markers of 
vitamin B12 status (methylmalonic acid, cystathione, and 2-methylcitrate) with episodic 
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memory scores and total brain volume (141).  In healthy male participants of the Veteran 
Affairs Normative Aging Study, both baseline plasma vitamin B12 and dietary recall assessed 
vitamin B12 intake were associated with increased constructional praxis abilities as assessed 
by spatial drawing three years after baseline measures (142).  This positive relationship may 
be due to individuals with low levels of vitamin B12.   In normo-cognitive community 
dwelling individuals aged 75-96 in Sweden, individuals with low vitamin B12 and low folate 
showed significantly worse scores on free-recall memory compared to those that had 
normal vitamin B12 and folate status.  However, there was no linear relationship between 
vitamin B12 or folate and episodic memory (143).  
Vitamin B12 and AD 
 
 It is crucial for the body to clear homocysteine that is produced in the methionine 
homocysteine cycle, as elevated homocysteine is linked to AD and other diseases including 
cardiovascular disease, Parkinson’s disease, depression, Crohn’s disease, inflammatory 
bowel disease and numerous types of cancers (144).   
 The literature surrounding the role of vitamin B12 status and supplementation in 
MCI or AD has been mixed.  On the one hand, vitamin B12 supplementation may slow brain 
atrophy in MCI when Omega-3 fatty acid levels are sufficient (145).  The same study also 
reported an improvement in executive function in participants who were given vitamin B12 
supplements; additionally, in participants with high levels of homocysteine, 
supplementation led to improved global cognition, episodic memory, and semantic memory 
(146).  A separate study showed that individuals in the top quintile for B12 intake showed 
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increased performance in working memory, but no differences in memory or executive 
function tests (147).   
However, many vitamin B12 supplementation trials have not been successful in 
improving brain structure and function.  Vitamin B12 supplementation in aged, cognitively 
normal adults with diabetes led to less grey matter volume in the left middle temporal pole 
and the left insula, two areas that are implicated in AD (148).  Similarly, aged adults with 
mildly elevated plasma homocysteine levels showed less total brain volume after 2 years of 
daily supplementation with 500 µg of vitamin B12 versus placebo tablet (149).    Folate, 
vitamin B6 and vitamin B12 supplementation in participants with AD that had normal B12, 
folic acid, and homocysteine levels led to reduced homocysteine levels but similar cognitive 
scores to placebo participants (150).  A startling finding of this study was that individuals who 
were receiving the supplements had significantly higher adverse events in the form of 
depressive symptoms (150).   
Taking into account the mixed literature, it is of interest to determine if serum 
vitamin B12 levels in non-supplemented individuals may serve as an effective biomarker for 
AD-related outcomes. 
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Abstract 
 Background: Obesity and insulin resistance are associated with neuropathology and 
cognitive decline in Alzheimer’s disease (AD). Objective: Ecto-nucleotide 
pyrophosphatase/phosphodiesterase 2, also called autotaxin, is produced by beige adipose 
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tissue, regulates metabolism, and is higher in AD prefrontal cortex (PFC). Autotaxin may be 
a novel biomarker of dysmetabolism and AD. Methods: We studied Alzheimer’s Disease 
Neuroimaging Initiative participants who were cognitively normal (CN; n=86) or had mild 
cognitive impairment (MCI; n=135) or AD (n=66). Statistical analyses were conducted using 
SPSS software. Multinomial regression analyses tested if higher autotaxin was associated 
with higher relative risk for MCI or AD diagnosis, compared to the CN group. Linear mixed 
model analyses were used to regress autotaxin against MRI, FDG-PET, and cognitive 
outcomes. Spearman correlations were used to associate autotaxin and CSF biomarkers due 
to non-normality. FreeSurfer 4.3 derived mean cortical thickness in medial temporal lobe 
and prefrontal regions of interest. Results: Autotaxin levels were significantly higher in MCI 
and AD. Each point increase in log-based autotaxin corresponded to a 3.5 to 5 times higher 
likelihood of having MCI and AD, respectively. Higher autotaxin in AD predicted 
hypometabolism in the medial temporal lobe [R2=0.343, p<0.001] and PFC [R2=0.294, 
p<0.001], and worse performance on executive function and memory factors. Autotaxin 
was associated with less cortical thickness in PFC areas like orbitofrontal cortex [R2=0.272, 
p<0.001], as well as levels of total tau, p-tau181, and total tau/Aβ1-42. Conclusions: These 
results are comparable to previous reports using insulin resistance. CSF autotaxin may be a 
useful dysmetabolism biomarker for examining AD outcomes and risk. 
Introduction 
 
Recent studies link obesity and metabolic dysfunction to decreased gray matter 
volume, less glucose metabolism, and other factors that contribute to Alzheimer’s disease 
(AD)[1-4]. Obesity may give rise to cerebral ischemia, which in turn is associated with brain 
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tissue degeneration [5]. Additionally, obese individuals are more likely to have higher insulin 
resistance (IR), defined as the progressive inability for insulin to bind to its receptor [6]. IR is 
correlated with temporal and frontal amyloid deposition and brain atrophy in late middle-
aged participants at risk for AD [2, 7], as well as less glucose metabolism in cognitively 
normal (CN) elders [8] and AD participants [1]. Resulting oxidative stress may induce cell 
damage in the brain [9].  
Numerous studies have also linked obesity with neuroinflammation and subsequent 
neurodegeneration, as induced by blood-brain barrier damage or microglial activation in the 
hippocampi of mice [9, 10]. Rats fed a high fat diet showed increased microglial activation 
as well as higher levels of the chaperone Hsp72, which are neuroprotective responses to 
brain injury [11]. Such high fat feeding also upregulates the expression of proinflammatory 
cytokines in the hypothalamus of rodents [12]. High levels of C-reactive protein, an 
inflammation marker, have been associated with increased white matter damage in 
individuals free of dementia [13]. Amylin oligomers and plaques were present in diabetic 
patients’ temporal lobe gray matter and absent in controls [14]. In a subsequent study, rats 
that overexpressed human amylin in the pancreas had elevated levels of brain pro-
inflammatory cytokines, as well as suppressed anti-inflammatory expression [15]. 
While it is increasingly clear that metabolic dysregulation may play a role in AD, 
there are currently no established biomarkers in cerebrospinal fluid (CSF) that may reflect 
central metabolic dysfunction. CSF insulin may not be a reliable biomarker because 
individuals with type 2 diabetes show reduced insulin uptake in the brain, potentially due to 
reduced transport across the blood-brain barrier when an individual maintains constant 
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high blood insulin levels [8]. Ecto-nucleotide pyrophosphatase/phosphodiesterase 2 
(ENPP2), also known as autotaxin, is an enzyme derived from beige adipose that aids in 
glucose metabolism regulation and adipose tissue expansion [16] and has been shown to be 
elevated in the brains of AD subjects versus controls [17]. Autotaxin expression is an 
outcome of the accumulation of triglycerides in the adipocyte [18]. Autotaxin is mostly 
expressed in the human brain, placenta, ovary, and small intestine, and stimulates the 
formation of lysophosphatidic acid (LPA) [19].  
In the central nervous system, leptomeningeal cells in the pia mater, as well as 
astrocytes and oligodendrocytes, are hypothesized to secrete autotaxin [20]. LPA is a lipid-
based growth factor and signaling molecule found in all mammalian cells, which promotes 
the generation of tissue fibrosis in vivo and in vitro, as well as neurotransmitter release and 
cell contraction and aggregation via utilization of G protein-coupled receptors [21, 22]. Rat 
neuronal cell culture work indicates that LPA administration leads to cortical folding and 
premature differentiation of cells [22]. Normal weight mice who were injected with LPA 
showed deficits in insulin response to glucose, and pancreatic beta-cells showed impaired 
insulin release when exposed to LPA [23]. Intriguingly, rats administered LPA showed 
increased blood-brain barrier permeability, suggesting that the effects of elevated autotaxin 
levels may be due to central and systemic factors [24]. EDG-2, an LPA receptor gene, is 
overexpressed in growing preadipocytes and may be an important regulator of adipose 
tissue development [25]. Obese women display positive correlations between serum 
autotaxin and fasting glucose [26]. Curiously, body mass index (BMI) and autotaxin showed 
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no significant correlation in this cohort, indicating that autotaxin may be more of a product 
of IR, as opposed to the extent of obesity in an individual.  
Importantly, some evidence suggests that autotaxin may play a role in AD, whereas 
the role of other metabolic biomarkers may be less clear. Individuals with AD-like dementia 
showed significantly higher gene expression of autotaxin in the frontal cortex, as compared 
to control brains [17]. Additional research is warranted to elucidate the association of high 
autotaxin levels with established AD biomarkers, cognitive function, and prefrontal cortex 
(PFC) and medial temporal lobe (MTL) brain volume and glucose metabolism in AD. PFC was 
a target area because our previous associations with IR are most consistent in that region 
[7, 8, 27-29], and that obesity across the lifespan is consistently associated with prefrontal 
atrophy [3]. Additionally, autotaxin in AD has only been examined in frontal cortices [17]. 
MTL is relevant to AD onset and progression, and we have shown that it is also sensitive to 
metabolic dysfunction.  
In this study, data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were 
used to examine CSF autotaxin peptide levels among 287 individuals (75.06 ± 6.89 years of 
age) who were diagnosed as being CN or having late mild cognitive impairment (MCI) due to 
AD or early AD. Autotaxin was regressed against cortical thickness (CT) and 
fluorodeoxyglucose (FDG) values in PFC and MTL, to examine if autotaxin was related to 
frontal and temporal atrophy and hypometabolism akin to our findings with IR [7, 8, 27, 28]. 
Relationships with neuropsychological function and traditional CSF biomarkers were also 
ascertained. The purpose of this study was to determine if CSF-derived autotaxin may be a 
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biomarker for metabolic dysfunction in the brain and could be associated with AD 
neurological outcomes.  
Materials and Methods 
 
Participants  
 
Data from 287 adults aged 56 to 89 were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). The ADNI was launched 
in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, 
MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging 
(MRI), positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of MCI and 
early AD. For up-to-date information, see http://www.adni-info.org. Written informed 
consent was obtained from all ADNI participants at their respective ADNI sites. The ADNI 
protocol was approved by site-specific institutional review boards. Baseline mass 
spectrometry data for autotaxin was available for 86 CN, 135 MCI, and 66 AD participants. 
By month 24, MCI participants were classified as either remaining stable (MCI-S, n=80) or 
progressing to AD (MCI-P, n=55). CN subjects had MMSE scores between 24 and 30, a CDR 
score of 0, and no dementia. Participants were classified as MCI if they had an MMSE score 
between 24 and 30, a CDR score of 0.5, complaints of memory loss, and objective memory 
loss measured on the Wechsler Memory Scale Logical Memory II. Probable AD was defined 
as MMSE scores between 20 and 26, a CDR score of 0.5 or 1.0, and meeting NINCDS/ADRDA 
criteria for probable AD. For additional information, see ADNI Procedures Manual 
(http://adni.loni.usc.edu). Details of the consensus procedure by the ADNI Conversion 
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Committee are described elsewhere[1]. Other baseline data included demographics, 
structural MRI for PFC and MTL CT, neural glucose metabolism as determined by FDG 
uptake, APOE4 genotype, CSF and serum biomarkers, BMI, and neuropsychological 
performance. While amyloid imaging was also of interest, baseline scans were not analyzed 
due to small sample size (n=20).  
Mass spectrometry and fasting glucose 
 
Data were downloaded from the Biomarkers Consortium CSF Proteomics MRM 
dataset. As described previously[29], the ADNI Biomarkers Consortium Project investigated 
the extent to which selected peptides, measured with mass spectrometry (MS), could 
discriminate among disease states. Briefly, Multiple Reaction Monitoring-MS (MRM-MS) 
was used for targeted quantitation of 567 peptides representing 221 proteins in a single run 
(Caprion Proteome Inc., Montreal, QC, Canada). Analyte values of ENPP2 are in arbitrary 
signal units on a natural log scale. Fasting insulin was assayed using a plasma multiplex 
immunoassay panel (http://adni.loni.usc.edu/). Fasting glucose was derived from a standard 
laboratory test. Insulin and glucose were used to calculate the homeostatic model 
assessment, HOMA-IR [30]. Analyses for this report focused on the autotaxin peptide 
WWGGQPLWITATK. This peptide performed better in predicting glucose metabolism and 
cortical thickness than ENPP2 SYPEILTLK in preliminary stepwise regression analyses. To 
confirm that autotaxin reflected central dysmetabolism, established metabolic and 
inflammatory biomarkers in CSF were regressed against autotaxin, including insulin-like 
growth factor binding protein 2 (IGFBP2) peptides, pyruvate kinase isozymes M1/M2, 
neurosecretory protein VGF, fructose-bisphosphate aldolase A, cholecystokinin and IL-6 
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receptor [31, 32]. These were the only metabolic or metabolic-related indices available in 
the CSF for ADNI. 
APOE genotype 
 
The ADNI Biomarker Core at the University of Pennsylvania conducted APOE ε4 
genotyping. We characterized participants as being “non-APOE4” (i.e., zero APOE ε4 alleles) 
or “APOE4” (i.e., one to two APOE ε4 alleles).  
Amyloid and tau CSF biomarkers 
 
CSF sample collection, processing, and quality control of p-tau181, total tau, and Aβ1-
42 are described in the ADNI1 protocol manual (http://adni.loni.usc.edu/) and Shaw et al. 
[33]. 
Clinical and cognitive assessments 
 
Baseline global cognition and assessment scores included the Mini-Mental State 
Examination (MMSE), clinical dementia rating-sum of boxes (CDR-sob), and AD assessment 
scale-cognitive subscale 11 (ADAS-cog11). The ADNI1 procedures manual describes 
diagnostic criteria (http://adni.loni.usc.edu/). The various tests that comprise executive 
function and memory factor are described elsewhere[34].  
MRI  
 
T1-weighted images, collected on 1.5T MR imaging units with a resolution of 1.25 x 
1.25 x 1.25 mm [35], were pre-processed using FreeSurfer 4.3 [36]. As described previously 
[2], this software corrects for motion, deskulls, bias corrects, segments, and parcellates gray 
and white matter into labeled cortical areas. We chose to examine CT instead of volume, as 
CT is typically considered a more sensitive index of gray matter pathology in participants 
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who are at-risk [37] or have AD [38]. To contain type 1 error, we first explored one broad 
region of interest (ROI) in bilateral prefrontal cortex and one ROI in bilateral medial 
temporal lobe, followed by finer grained associations in sub-ROI if an initial omnibus 
analysis in a given broad ROI was significant. In the PFC, bilateral sub-ROIs included: 1) pars 
orbitalis; 2) pars triangularis; 3) caudal middle frontal; 4) rostral middle frontal; 5) superior 
frontal; 6) frontal pole; 7) lateral orbitofrontal; and 8) medial orbitofrontal. These areas are 
very similar to ROI chosen in previous reports on metabolic dysfunction with regional 
amyloid [2] and FDG [1]. In the MTL, bilateral sub-ROI included hippocampal volume (where 
CT is not calculated by FreeSurfer) and CT in: 1) medial temporal gyrus; 2) parahippocampal 
gyrus; and 3) entorhinal cortex. Bilateral pre-central gyrus was chosen as a control ROI, an 
area that shows little association with dysmetabolism and brain atrophy in middle-aged 
participants [7] or glucose metabolism in AD[1].  
FDG-PET 
 
Acquisition is described elsewhere [27, 39]. Images were resliced to a 1.5 mm3 voxel 
resolution in a 160 x 160 x 96 spatial matrix, intensity normalized to pons to derive the 
standardized uptake volume ratio (SUVR), smoothed using an 8mm Gaussian kernel, and 
normalized to Montreal Neurological Institute space. Due to the poorer native resolution of 
the FDG-PET images and smoothing to reduce noise, only the two broad ROI in PFC and 
medial temporal lobe were used. Similarly broad ROI have been used to examine 
relationships between dysmetabolism and FDG-PET [27]. 
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Statistical analyses  
 
All statistical analyses were conducted using SPSS 23.0 software (IBM Corp., Armonk, 
NY). All analysis models except for cognition included the following covariates: age at 
baseline, sex, BMI, APOE ε4 genotype, and either baseline diagnosis or MCI conversion. The 
random effect of Subject was also covaried. For executive function, memory and global 
assessments, education was added as a covariate but not baseline diagnosis or MCI 
conversion, because cognitive assessments directly inform how participants are clinically 
classified. Linear mixed models, followed by least significant differences (LSD) post-hoc 
tests, were used to test if autotaxin levels differed by baseline diagnosis (CN, MCI, AD) or 
MCI conversion (MCI-S or MCI-P). Multinomial regression analyses tested if higher autotaxin 
was associated with higher relative risk ratios for an MCI or AD diagnosis, with CN as the 
reference group. Logistic regression was similarly used to assess increased risk of being MCI-
P relative to MCI-S based on autotaxin.   
Mixed model analyses were also performed to regress autotaxin against metabolic, 
MRI, FDG-PET, and cognitive outcomes. The main effect of autotaxin and its interaction with 
baseline diagnosis or MCI conversion were tested in a given model. Previous work has 
suggested that systemic IR is associated with neural outcomes like less regional FDG-PET in 
AD, but show different relationships in MCI-S or MCI-P depending on the brain region [27]. 
For the MRI analyses, to robustly contain type 1 error, an initial multivariate repeated 
measures omnibus was initially conducted for a broad PFC or medial temporal ROI, as 
described elsewhere [40], where each ROI was composed of several sub-ROI selected a 
priori based on our prior work [1, 2]. Briefly, this technique determines if there is an overall 
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significant association with all sub-ROIs, allowing subsequent analyses to investigate each 
sub-ROI to determine where omnibus signal was derived without Bonferroni or similar 
corrections [41]. Even so, as a further type 1 error check described by Willette et al. [27], 
Holm-Bonferroni correction [42] was used to adjust the family-wise error rate to 0.05. 
Specifically, for a significant follow-up interaction for a given sub-ROI, autotaxin levels were 
regressed against CT for CN, MCI, and AD separately, or 3 null hypotheses per ROI. A p value 
of 0.017 was needed among one of the groups to achieve significance, followed by 0.025 
and 0.050.  
Lastly, as described by the ADNI Biomarker Core [29], CSF and plasma analyte values 
were log-transformed to achieve normality. With the exception of AD biomarkers, all 
variables had homoscedastic variance and a normal distribution. Due to violations in 
regression diagnostics for p-tau181, total tau, and Aβ1-42 (see below), the non-parametric 
Spearman’s statistic was used to correlate autotaxin and CSF biomarker values.  
Results 
 
Demographics and data summary 
 
  Summary information is listed in Table 3.1. All variables were normally distributed 
except for Aβ1-42 (D=0.130, p<0.001), Total tau (D=0.121, p<0.001), and p-tau (D=0.104, 
p<0.001), as fit against normal Q-Q plots was non-linear. Data transforms did not resolve 
non-normality. Non-parametric correlations were therefore conducted between autotaxin 
and CSF amyloid and tau biomarkers.  
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Baseline diagnosis: differences in autotaxin levels 
 
  Linear mixed models showed a main effect of baseline clinical diagnosis on autotaxin 
[F(2,286)=3.100, p=0.047]. There was a significant increase in log-scaled autotaxin from CN 
to either MCI [Mean Difference ± SE=0.078±0.036, p=0.029] or AD [Mean Difference ± 
SE=0.094±0.043, p=0.029], but not between MCI and AD [Mean Difference ± 
SE=0.016±0.038, p=0.665].   
  As a follow-up analysis, multinomial logistic regression was then used to examine if 
CSF autotaxin expression predicted an increased likelihood of being MCI or AD. The 
reference group was CN. The likelihood ratio statistic [c2=5.990, p=0.050] indicated that 
higher autotaxin levels predicted a higher Odds Ratio for being MCI [β±SE=1.248±0.605, 
OR=3.485, 95% CI=1.065 to 11.397, Wald=4.264, p=0.039] or AD [β±SE=1.597±0.747, 
OR=4.940, 95% CI=1.134 to 21.351, Wald=4.574, p=0.032]. These results suggest that 
autotaxin levels were higher in memory impaired versus CN participants, and that per point 
increase in log-based autotaxin values corresponded to a roughly 3.5 to 5 times increase in 
the odds of having some degree of clinically relevant memory impairment. For MCI 
conversion by 24 months, there was no significant difference between MCI-S and MCI-P. 
Baseline autotaxin levels also did not predict likelihood of MCI conversion [c2=0.177, 
p=0.674]. 
Associations of autotaxin with metabolic and inflammatory indices 
 
  Next, to validate autotaxin as an energy metabolism biomarker, CSF autotaxin levels 
were regressed against total body mass, peripheral and CSF metabolic and inflammatory 
biomarkers (Table 3.2), as well as used to predict likelihood of having pre-diabetes or type 2 
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diabetes. We found that higher autotaxin was related to higher fasting glucose, several 
established biomarkers of metabolism in the CSF, CSF interleukin-6, and that higher levels 
per point increase reflected a 300% greater likelihood of having pre-diabetes or type 2 
diabetes.  
ROI analysis: PFC and MTL CT  
 
  For bilateral PFC CT, a multivariate omnibus was conducted in one broad PFC ROI 
incorporating several sub-ROI from FreeSurfer areas, to minimize type 1 error [41]. The 
main effect of autotaxin and its interaction with baseline diagnosis were investigated. The 
interaction tested if autotaxin differentially predicted less CT among CN, MCI, or AD 
participants. There was a marginal, within-subject Regions x Baseline Diagnosis x Autotaxin 
interaction after Huynh-Feldt correction [F(14,1200)=1.784, p=0.066], which became 
significant after removing one outlier with a high autotaxin value (18.31) [F(14,1197)=2.031, 
p=0.032]. As indicated in Table 3.3, even after applying Holm-Bonferroni correction, higher 
autotaxin was associated with thinner CT in most PFC sub-ROI for AD participants, such as 
medial orbitofrontal cortex (Fig. 3.1A) and only in Pars Orbitalis for MCI, while the CN group 
showed negative and positive associations. By contrast, the omnibus for the one broad 
medial temporal ROI was non-significant, where further analyses were not pursued to guard 
against type 1 error. In the pre-central gyrus control region, there was no significant main 
effect of autotaxin or interaction with baseline diagnosis. 
ROI analysis: PFC and MTL glucose metabolism 
 
  For FDG-PET, an Autotaxin * Baseline Diagnosis interaction [F(2,146)=3.106, 
p=0.048] showed that higher autotaxin predicted less glucose uptake in the broad PFC ROI 
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for AD subjects [β±SE=-0.127±0.027, t(1,35)=-4.708, p<0.001], marginally for CN [β±SE=-
0.074±0.041, t(1,35)=-1.822, p=0.077] and not for MCI [β±SE=0.043±0.029, t(1,70)=1.497, 
p=0.139]. Removal of the same autotaxin outlier from the PFC CT analysis did not affect the 
association in the AD group [β±SE=-0.116±0.032, T(1,34)=-3.610, p=0.001] (Fig. 3.1B). In 
addition, the Autotaxin * MCI Conversion interactions were non-significant for PFC.  
  Similar relationships were seen in the broad temporal ROI. A Baseline Diagnosis * 
Autotaxin interaction [F(2,146)=14.175 p<0.001] revealed that higher autotaxin was 
associated with less MTL glucose metabolism in AD [β±SE=-0.586±0.026, t(1,37)=-4.334 
p<0.001] and CN participants [β±SE=-0.429±0.049, t(1,35)=-2.773 p=0.009], but not in MCI 
[β±SE=0.189±0.027, t(1,72)=1.619 p=0.110].  
 FDG uptake in the pre-central gyrus control region did not show a main effect of 
autotaxin or interaction with baseline diagnosis or MCI conversion. 
Cognition: global and executive function factor scores 
 
As shown in Table 3.4, separate linear mixed models indicated that per point 
increase in autotaxin, scores were lower for the executive function and memory factors, but 
not for global cognition and function scores.  
CSF biomarkers: Aβ1-42, total tau, and p-tau 
 
  Across all participants, the Spearman’s statistic showed that higher autotaxin was 
associated with higher levels of total tau, p-tau181, and total tau/Aβ1-42 (Table 3.5).  
Discussion 
 
  In this study, we hypothesized that CSF-derived autotaxin may be a biomarker for 
brain metabolic dysfunction relevant to AD. Strikingly, higher autotaxin predicted less 
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bilateral PFC and MTL glucose uptake in individuals with AD, with similar effects seen in 
bilateral PFC CT. Results also showed that participants who had MCI or AD had significant 
increased log-scaled autotaxin. IR shows a similar relationship with PFC and MTL FDG-PET in 
late middle-aged participants [28], and among aged CN adults with type 2 diabetes [8] or AD 
[27], where the ADNI AD group for the previous report and this cohort show similar results.  
  Higher autotaxin correlated with established metabolic biomarkers and higher risk 
for pre-diabetes and type 2 diabetes. CSF ENPP2 was moderately associated with peripheral 
fasting glucose, but not BMI, where others have noted similar findings [26]. Furthermore, 
per point increase in autotaxin, executive function and memory factor scores were lower. 
Similarly, a decreased insulin sensitivity index in rhesus monkeys [43] was associated with 
less PFC gray matter and mediated worse motor-planning executive function performance. 
Higher HOMA-IR in aged humans with AD was also related to less MTL and PFC glucose 
metabolism [27], respectively mediating worse memory and executive function factor 
scores (unpublished data). Several studies have found similar associations between 
metabolic dysfunction, PFC outcomes, and executive function. Diabetes was significantly 
associated with worse cognitive performance and attention deficit in young adults without 
dementia [44]. In a cohort of bariatric surgery patients, as HOMA-IR levels decreased 
following the surgery, cognition scores improved [45]. Taken together, autotaxin shows a 
pattern of relationships with established metabolism biomarkers, MTL and PFC-specific 
outcomes, and related cognitive dysfunction that may reflect central dysmetabolism and is 
similar to our previous findings with IR. 
 56 
  Autotaxin was also positively correlated with levels of total tau, p-tau181, total 
tau/Aβ1-42, as well as p-tau181/Aβ1-42 to a marginal degree. This pattern suggests that CSF 
autotaxin predicts AD neuropathology in a manner similar to dysmetabolism. Chronic 
application of insulin in vitro in human cortical stem cells appeared to induce insulin 
resistance and inhibit tau dephosphorylation [46]. Higher IR among cognitively normal, 
APOE4 late middle-aged participants also predicted higher total tau and phosphorylated tau 
[47], but not CSF amyloid. Amyloidosis is scant in this late middle-aged cohort, but does 
show modest regional associations with higher IR [2]. ADNI did not have enough baseline 
amyloid scans (n=20) to warrant analysis with autotaxin.  
  This brings to question the underlying mechanism behind the correlation of 
autotaxin and AD-related outcomes. Individuals with high autotaxin may be more likely to 
be obese, causing an increase in IR, ischemia, and oxidative stress. Results of our study 
showed a weak association between systemic glucose and CSF autotaxin. As an alternative 
or interrelated mechanism, autotaxin stimulates the release of LPA, which may be 
detrimental [21, 22]. LPA has been shown to prompt neurite withdrawal and tau 
phosphorylation in neuroblastoma cells [48]. Addition of LPA to neuroblastoma cells led to 
increased immunoreactivity with antibodies that react with tau phosphorylation [17]. 
  There are several study limitations to address. Regression diagnostic issues were 
encountered for total tau, p-tau181, and Aβ1-42, requiring non-parametric analyses. Autotaxin 
levels did not differ in MCI conversion or contribute to MCI conversion risk, nor were there 
significant interactions with MCI conversion, which may be due to small sample size. 
Instead, baseline values were widely dispersed in the MCI converter group. This mirrors IR 
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MCI interactions [1]. No associations were found with Aβ levels, but there were significant 
associations with tau and p-tau181, as well as tau to amyloid ratios. Given that the mass 
spectrometry panel was only available at baseline, we were unable to longitudinally assess 
autotaxin levels and various outcomes. While longitudinal predictions would be useful, it 
was beyond the scope of this report, which was to systematically assess if autotaxin may be 
a relevant AD biomarker. While autotaxin was associated with fasting glucose, it was 
surprising that it was not associated with systemic insulin or HOMA-IR. This may be because 
insulin was derived from a plasma multiplex, and the values are lower than ELISA. 
Nonetheless, autotaxin was associated with fasting glucose, risk for pre-diabetes and type 2 
diabetes, and was associated with many established metabolic factors in CSF. It also shows 
a pattern of results comparable to HOMA-IR and either brain atrophy or FDG-PET[7, 27, 28]. 
The non-significance of MTL ROI CT was unexpected; however, it also provides direction for 
future research. Glucagon-like peptide-1 (GLP-1) may be a potential element in this 
phenomenon. GLP-1 stimulates the release of insulin as well as downregulates the release 
of glucagon and breakdown of amyloid-β protein precursor [49]. GLP-1 receptor production 
in the aged mouse medial PFC was decreased compared to young mice, but no similar 
relationship was seen in the hippocampal regions [49]. 
  In summary, this study demonstrates that CSF-derived autotaxin in elders correlated 
with greater odds for having MCI or AD, hyperglycemia, AD neuropathology related to total 
tau, p-tau181, and the total tau/Aβ1-42 ratio, less gray matter CT in PFC, hypometabolism in 
PFC and MTL, and worse executive function and memory scores. These results support the 
theory that autotaxin may be an indicator of central dysmetabolism for a variety of AD 
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outcomes. Further replication is necessary to determine if autotaxin predicts AD and tracks 
certain aspects of the disease. Future clinical and animal model work should consider 
examining this biomarker and its applications as a potential target for pharmacologic 
therapies in the setting of glucose dysregulation and AD. Such work should also examine 
how autotaxin predicts changes in these outcomes over time. 
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Tables and Figures 
 
Table 3.1. Demographics and sample characteristics 
 
  CN MCI AD MCI-S MCI-P 
Age 75.70 ± 5.54 74.69 ± 7.35 74.98 ± 7.57 74.74 ± 6.96 74.63 ± 7.94 
Female 42 44 29 25 19 
Male 44 91 37 55 36 
Education 15.64 ± 2.97 16.00 ± 2.96 15.11 ± 2.96 16.33 ± 2.91 15.51 ± 3.00 
APoE ε4- 65 64 19 41 23 
APoE ε4+ 21 71 47 39 52 
CDR-sob 0.02 ± 0.11 1.56 ± 0.88 4.34 ± 1.56 1.41 ± 0.79 1.77 ± 0.97 
MMSE 29.05 ± 1.02 26.91 ± 1.74 23.52 ± 1.85 27.35 ± 1.62 26.27 ± 1.72 
ADAS-cog11 6.05 ± 2.90 11.72 ± 4.33 18.88 ± 6.71 10.70 ± 4.05 13.19 ± 4.32 
Memory factor 0.98 ±0.50 -0.15±0.57 -0.91±0.55 0.04 ± 0.57 -0.43 ± 0.45 
 
Numbers represent frequency or unadjusted mean ± SD. MCI-S, Stable MCI at 12 months. 
MCI-P, Progression to AD from MCI at 12 months. 
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Table 3.2. The association of autotaxin with CSF metabolic and inflammatory biomarkers. 
 
 β ± SE F value p value 
Fructose-bisphosphate aldolase A 0.415±0.097 18.551 <0.001 
Cholecystokinin 0.378±0.123 9.369 0.002 
Pyruvate Kinase Isozymes M1/M2 0.576±0.108 28.364 <0.001 
Neurosecretory protein VGF 0.574±0.162 12.614 <0.001 
IGFBP2 0.595±0.056 114.899 <0.001 
IL-6 receptor    
CN 0.102±0.011 93.830 <0.001 
MCI 0.067±0.010 45.705 <0.001 
AD 0.097±0.015 41.301 <0.001 
 
Model estimate beta values and SE of autotaxin for CSF metabolites and inflammation 
biomarkers. 
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Table 3.3. The interaction of clinical diagnosis and autotaxin on prefrontal cortex thickness. 
 
  CN MCI AD 
Cortical Thickness 
T 
value β ± SE 
T 
value β ± SE 
T 
value β ± SE 
Pars Orbitalis -1.519 -0.073 ± 0.048 -2.188 -0.073 ± 0.034* -4.253 -0.230 ± 0.054*** 
Pars Triangularis -4.300 -0.062 ± 0.014*** -1.914 -0.041 ± 0.021 -4.178 -0.102 ± 0.024*** 
Rostral Middle Frontal -0.073 -0.001 ± 0.013 -1.592 -0.028 ± 0.018 -4.180 -0.090 ± 0.022*** 
Lateral Orbitofrontal 3.214 0.046 ± 0.014** -0.260 -0.005 ± 0.020 -5.306 -0.122 ± 0.023*** 
Medial Orbitofrontal 1.178 0.020 ± 0.017 -0.664 -0.014 ± 0.021 -4.922 -0.127 ± 0.026*** 
Caudal Middle Frontal -1.208 -0.015 ± 0.013 1.146 0.021 ± 0.019 0.667 0.014 ± 0.021 
Superior Frontal -3.596 -0.062 ± 0.017** 0.178 0.004 ± 0.025 -1.705 -0.050 ± 0.029 
Frontal Pole 1.153 0.023 ± 0.020 1.378 0.034 ± 0.025 
-
10.925 -0.344 ± 0.031*** 
       
*p<0.05, **p<0.01, ***p<0.001 
Model estimate beta values and SE of autotaxin for prefrontal CT ROI. T values are for each 
clinical group. For each ROI, Holm-Bonferroni correction required successive p values of 
0.017, 0.025, and 0.050 for a given diagnostic group fit-line to be considered significant.  
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Table 3.4. The association of autotaxin with cognitive indices. 
 
Cognitive Parameter F value p value β ± SE 
ADAS-cog11 1.251 0.264 1.802 ± 1.611 
CDR-sob 0.831 0.363 0.405 ± 0.444 
Executive Factor 4.215 0.037 -0.464 ± 0.222 
Memory Factor 4.222 0.041 -0.333 ± 0.056 
MMSE 0.054 0.816 0.230 ± 0.606 
 
Model estimate beta values and SE of autotaxin for global indices and the executive 
function and memory factors. Bolded text indicates results with a significant p value. 
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Table 3.5. The association of autotaxin and AD CSF markers. 
 
CSF Biomarker p value Spearman's R value 
Aβ1-42 0.738 -0.020 
p-tau181 0.028 0.130 
p-tau181/Aβ1-42 0.070 0.108 
Total Tau 0.002 0.185 
Total Tau/Aβ1-42 0.018 0.141 
 
Due to regression diagnostics, parametric models were not conducted between autotaxin 
and CSF biomarkers. Bolded text indicates results with a significant p value. 
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Figure 3.1. Autotaxin and PFC region of interest analyses. The association between CSF 
autotaxin and baseline bilateral medial orbital PFC cortical thickness (A) or bilateral PFC 
FDG-PET glucose uptake (B), an index of glucose metabolism, among baseline diagnosis 
groups. The “blue circle”, “green triangle”, and “red star” symbols correspond to CN, MCI, 
and AD participants respectively. The R2 value refers to the proportion of variance in CT or 
FDG-PET uptake explained by autotaxin for a given group. ***p < 0.001. 
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Abstract 
 Background/Objective: Insulin-like growth factor binding protein 2 (IGFBP-2) 
regulates blood glucose levels, facilitates hippocampal synaptic plasticity and may have a 
predictive value for Alzheimer’s disease (AD) diagnosis.  Methods: IGFBP-2 levels were 
studied in plasma in 566 subjects and in cerebrospinal fluid (CSF) in 245 subjects across the 
AD spectrum from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Variants in the 
IGFBP-2 gene were examined. Linear mixed modeling in SPSS tested main effects of IGFBP-2 
and interactions with APOE4 on neurocognitive indices and biomarkers. Voxel-wise 
regression was used to gauge IGFBP-2 and regional gray matter and glucose metabolism 
associations. Results: Each point increase in IGFBP-2 corresponded to a 3 times greater 
likelihood of having mild cognitive impairment (MCI) or AD. IGFBP-2 showed beneficial 
associations with respect to cognitive scores in individuals with two APOE4 alleles. Higher 
IGFBP-2 predicted higher insulin resistance, but not CSF amyloid or tau. Voxel-wise analyses 
showed that plasma IGFBP-2 predicted lower grey matter volume and FDG metabolism in a 
large area spanning the frontal, temporal, and occipital lobes. CSF IGFBP-2 levels showed 
similar voxel-wise analysis results but were uniquely associated with CSF amyloid and tau. 
Analysis of single nucleotide polymorphisms (SNPs) in IGFBP-2 showed that subjects 
carrying risk alleles versus common alleles had increased risk of AD and lower memory 
scores. Voxel-wise analyses of these SNPs also implicated the hippocampus and prefrontal 
cortex.  Conclusions: IGFBP-2 is associated with AD risk and outcomes; plasma IGFBP-2 
provides stronger predictive power for brain outcomes, while CSF IGFBP-2 provides 
improved predictive accuracy for AD CSF biomarkers. 
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Introduction 
 
 Insulin-like growth factor binding proteins (IGFBP) serve to bind insulin-like growth 
factors (IGF) to regulate their concentrations and consequently metabolic activity [1]. 
IGFBPs are central for the transport of IGF to its receptor site, and have the ability to 
enhance binding to the receptor site or inhibit the access of IGF to its receptors by creating 
strong bonds, lowering binding potential [2]. IGFBP is centrally important in regulating 
blood glucose levels, although in excess can be a marker of disease. IGFBP-2, in particular, 
binds to both IGF-1 and IGF-2, and can inhibit IGF functions such as DNA synthesis, cell 
proliferation, and cell death, as well as glucose and amino acid uptake in cells [3, 4]. For 
example, transgenic mice that overexpressed IGFBP-2 showed significantly higher blood 
glucose levels than controls at 30, 60 and 90 minutes during an oral glucose tolerance test, 
as well as lower levels of GLUT4--the insulin-dependent glucose transporter--at cell surfaces 
compared to controls [5]. Abnormally high IGFBP-2 levels are often an indicator of severe 
catabolic events, such as gastric cancer, anorexia nervosa and renal failure [6-8]. In a study 
of 625 men and women aged 70 and older, plasma IGFBP-2 significantly predicted mortality 
from all causes after adjusting for markers of body composition, as well as fasting glucose 
and insulin [9]. 
Alzheimer’s disease (AD) has been associated with defects in the insulin signaling 
pathway. Higher levels of insulin resistance (IR) were correlated with increased regional 
amyloid deposition and atrophy in frontal and temporal areas of the brain in late middle-
aged adults [10, 11]. In addition, higher IR was associated with decreased cerebral glucose 
metabolic rate and worse memory scores in cognitively normal adults with pre-diabetes or 
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type 2 diabetes [12]. Animal models provide evidence that IGFBP-2 may play a role in AD. 
Over-expression of IGFBP-2 in mice led to decreased weights of the hippocampus, 
cerebellum, olfactory bulb and prefrontal cortex at 12 weeks, compared to controls [13]. An 
important study in humans utilized ex vivo tissue from individuals across the AD spectrum, 
and showed that IGF resistance was related to beta amyloid (Aβ) plaques, other markers of 
AD, and worse ante-mortem cognition [14]. Some associations may be compartment-
specific, as CSF but not plasma IGFBP-2 levels were higher in 92 AD patients versus 72 
healthy controls [15], where CSF IGFBP-2 levels were positively correlated with total tau and 
phosphorylated-181-tau (p-tau). Also, APOE4 alleles have been shown to play a role in 
insulin metabolism and cognitive function [16].  Cognitively normal (CN) and AD participants 
who were APOE4 homozygous showed improvements in memory with lower doses of 
intranasal insulin as compared to individuals who were not APOE4 homozygous [16].  
Additionally, a study using euglycemic hyperinsulinemic clamps in individuals with impaired 
glucose tolerance and healthy controls showed that IGFBP-2 was the only insulin signaling 
molecule assayed to independently predict bioactive levels of IGF-1 in both groups; this 
study showed a negative correlation between IGFBP-2 and IGF-1 [17]. 
As biomarkers become increasingly more important in tracking AD diagnosis and 
progression, and metabolic markers have gained more interest, additional research is 
needed to explore the role of IGFBP-2 in AD. We hypothesize that IGFBP-2 levels would be 
positively associated with more brain atrophy, less neuronal glucose uptake, and impaired 
cognitive function. In this study, we utilized data from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) to examine plasma levels of IGFBP-2 among 566 individuals 
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that were cognitively normal (CN), or had mild cognitive impairment (MCI) or AD. This is the 
first study, to our knowledge, to systematically study the relationship between peripheral 
IGFBP-2 levels and related single nucleotide polymorphisms (SNPs) with neural, cognitive, 
and biomarker outcomes relevant to AD, including peripheral inflammatory markers like 
Interleukin-6 (IL-6) receptor and C-peptide. On an exploratory basis in a subset of 245 
subjects, we also examined how CSF mass spectrometry IGFBP-2 peptide was related to 
these outcomes as compared to plasma IGFBP-2. 
Materials and Methods 
 
Participants 
Data from middle-aged to aged adults were obtained from the ADNI database 
(http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, 
led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), 
other biological markers, and clinical and neuropsychological assessment can be combined 
to measure the progression of MCI and early AD. For up-to-date information, see 
http://www.adni-info.org. Written informed consent was obtained from all ADNI 
participants at their respective ADNI sites. The ADNI protocol was approved by site-specific 
institutional review boards. All analyses used in this report only included baseline data. 
Baseline plasma data for IGFBP-2 was available for 566 participants: 58 CN, 396 MCI, and 
112 AD.  Baseline CSF data for IGFBP-2 was available for 245 subjects: 45 CN, 134 MCI, and 
66 AD. Baseline genomic data was available for 756 participants: 229 CN, 354 MCI, and 173 
AD. 
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Participants with MCI had the following diagnostic criteria: 1) memory complaint 
identified by the participant or their study partner; 2) abnormal memory as assessed by the 
Logical Memory II subscale from the Wechsler Memory Scale- Revised, with varying criteria 
based on years of education; 3) Mini-Mental State Exam (MMSE) score between 24 and 30; 
4) Clinical dementia rating of 0.5; 5) Deficits not severe enough for the participant to be 
diagnosed with Alzheimer’s disease by the site physician at screening. Participants with AD 
met similar criteria, however, were required to have an MMSE score between 20 and 26, a 
clinical dementia rating of 0.5 or 1.0, and NINCDS/ADRDA criteria for probable AD. 
Mass Spectrometry and Fasting Glucose 
 
Data were downloaded from the Biomarkers Consortium CSF Proteomics MRM 
dataset and the Biomarkers Consortium Plasma Proteomics Project RBM multiplex. As 
described previously [18], the ADNI Biomarkers Consortium Project investigated the extent 
to which selected peptides, measured with mass spectrometry, could discriminate among 
disease states. Briefly, Multiple Reaction Monitoring-MS (MRMMS) was used for targeted 
quantitation of 567 peptides representing 221 proteins in a single run (Caprion Proteome 
Inc., Montreal, QC, Canada). Fasting insulin was assayed using a plasma multiplex 
immunoassay panel (http://adni.loni.usc.edu/), which we note produce consistently lower 
insulin values than a standard ELISA kit. Fasting glucose was derived from a standard lab 
test. Insulin and glucose were used to calculate the homeostatic model assessment, HOMA-
IR. Analyses for this report focused on IGFBP-2 levels, which were assayed in the plasma 
multiplex panel and CSF proteomics panel, for which the peptide LIQGAPTIR was chosen, 
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which performed better in most analyses (data not shown). For proinflammatory markers, 
C-peptide and IL-6 receptor levels were derived from the plasma multiplex. 
APOE Genotype 
 
 The ADNI Biomarker Core at the University of Pennsylvania conducted APOE ε4 
genotyping. We characterized participants as having zero APOE4 alleles, one APOE4 allele, 
or two APOE ε4 alleles.  
Amyloid and Tau CSF Biomarkers 
 
CSF sample collection, processing, and quality control of p-tau, total tau, and Aβ1-42 
are described in the ADNI1 protocol manual (http://adni.loni.usc.edu/) and Shaw et al [19]. 
Neuropsychological Assessment 
ADNI utilizes an extensive battery of assessments to examine cognitive functioning 
with particular emphasis on domains relevant to AD. A full description is available at 
http://www.adni-info.org/Scientists/CognitiveTesting.aspx. All subjects underwent clinical 
and neuropsychological assessment at the time of scan acquisition. Neuropsychological 
assessments included: The Clinical Dementia Rating sum of boxes (CDR-sob), Mini-Mental 
Status Exam (MMSE), Auditory Verbal Learning Test (RAVLT), and AD Assessment Schedule - 
Cognition (ADAS-Cog). A composite memory score encompassing the RAVLT, ADAS-COG, 
MMSE, and Logical Memory assessments was also utilized [20].  Additionally, a composite 
executive function score comprising Category Fluency—animals, Category Fluency—
vegetables, Trails A and B, Digit span backwards, WAIS-R Digit Symbol Substitution, Number 
Cancellation and 5 Clock Drawing items was used[21].  These composite scores were used in 
formal analyses to represent global memory and executive function among subjects. 
 78 
Magnetic Resonance Imaging (MRI) Acquisition and Pre-Processing 
 
T1-weighted MRI scans were acquired within 10-14 days of the screening visit 
following a back-to-back 3D magnetization prepared rapid gradient echo (MP-RAGE) 
scanning protocol described elsewhere [22]. Images were pre-processed using techniques 
previously described [11]. Briefly, the SPM12 “New Segmentation” tool was used to extract 
modulated gray matter (GM) volume maps. Maps were smoothed with an 8mm Gaussian 
kernel and then used for voxel-wise analyses.  
FDG-PET 
 
FDG-PET acquisition and pre-processing details have been described previously [22]. 
Briefly, 185 MBq of [18-153-F]-FDG was injected intravenously. After 30 minutes, six 5-
minute frames were acquired. Frames of each baseline image series were co-registered to 
the first frame and combined into dynamic image sets. Each set was averaged, reoriented to 
a standard 160 x 160 x 96 voxel spatial matrix of resliced 1.5 mm3 voxels, normalized for 
intensity, and smoothed with an 8 mm FWHM kernel. In order to derive the standardized 
uptake value ratio (SUVR), pixel intensity was normalized according to the pons since it 
demonstrates preserved glucose metabolism in AD [23]. Normalization to the pons 
removed inter-individual tracer metabolism variability. The Montreal Neurological Institute 
(MNI) template space was used to spatially normalize images using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). A subset of subjects underwent FDG-
PET scans and analyses included in this report. 
Statistical Analysis 
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All analyses were conducted using SPSS 24 (IBM Corp., Armonk, NY) or SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). Linear mixed effects models tested 
the main effects of plasma or CSF IGFBP-2 on cognitive scores, biomarkers, Baseline 
Diagnosis, and their outcomes of interest in SPSS 24. Main effects and interactions with 
APOE or Baseline Diagnosis were tested in a single model. Covariates included age at 
baseline, sex, and baseline diagnosis in all models. An additional covariate, years of 
education, was included when analyzing memory and cognitive performance.  Outcomes 
included neuropsychological performance, modulated GM maps and FDG maps, and CSF 
biomarkers including Aβ1-42, t-tau and p-tau. Binomial logistic regression was also used to 
assess the odds ratio of a given participant being diagnosed as MCI or AD versus the CN 
reference group. Linear regression was used in PLINK to assess genetic associations.  
To correct for type 1 error in non voxel-wise analyses, as described previously [24, 
25], Holm-Bonferroni correction was used for each set of analyses. This closed test 
procedure maintains a family-wise P value = 0.05 by requiring unadjusted P values of 0.05 
divided by x, x being the number of null hypotheses tested. For 4 cognitive tests, for 
example, P values of .0125, .025, .0375, and .050 are successively needed among any test to 
proceed with testing in the closed set. For sets that were not robust under Holm-Bonferroni 
correction, a less strict form of correction was used. Specifically, omnibus testing using 
MANCOVA incorporating all dependent variables of the set was conducted, where a 
significant main effect or Baseline Diagnosis interaction allowed further testing of all 
outcomes as follow-up tests. A family-wise error rate of .05 is maintained using this 
approach [26].  
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For voxel-wise analysis, 2nd-level mixed models tested main effects of IGFBP-2 on 
regional GM volume and FDG, controlling for age, sex, education, and Baseline Diagnosis. 
The thresholds were set at P < .005 (uncorrected) and P < .05 (corrected) for voxels and 
clusters respectively. Results were considered significant at the cluster level. As described 
previously [24], in order to reduce type 1 error, we utilized a GM threshold of 0.2 to ensure 
that voxels with <20% likelihood of being GM were not analyzed. For GM, Monte Carlo 
simulations in ClusterSim (http://afni.nimh.nih.gov/afni/doc/manual/3dClustSim) were used 
to estimate that 462 contiguous voxels were needed for such a cluster to occur at P < 0.05. 
For FDG voxel-wise analyses, Monte Carlo simulations in ClusterSim were used to estimate 
that 224 contiguous voxels were needed for such a cluster to occur at P < 0.05.   
Genomic Data Processing and Quality Control 
 
Genomic data underwent stringent quality control (QC) by assessing concordance 
with Hardy-Weinberg equilibrium (HWE) scrutinized data for Mendelian inheritance errors. 
Single Nucleotide Polymorphisms (SNPs) were filtered based on HWE P-value > 0.00001 and 
MAF >0.05% and a call rate of 95%. Samples with greater than 5% missingness were 
removed. Sample genotypes were imputed using 1000Genomes data with Shapeit/Impute2 
software following the protocol outlined here [27]. SNPS with call rates <95 % or R2 ≤ 0.3 
were removed leaving 2,976,223 imputed and genotyped SNPs after quality control. All 
analyses were conducted using PLINK v1.9 (http:// www.cog-genomics.org/plink2).  
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Results 
 
Data Summary 
 
Clinical, demographic, and CSF data for subjects with plasma IGFBP-2 are presented 
in Table 4.1. There were no differences based on years of education or age at baseline 
between CN, MCI or AD subjects. As expected for this ADNI sub-population, there was a 
significant difference in the percentage of APOE4 carriers and in cognitive function. 
Subsequently, analyses were conducted with plasma IGFBP-2.  Demographic data for 
subjects with CSF IGFBP-2 are presented in Supplemental Table 4.1. See Supplemental Text 
4.1 for analyses that used CSF IGFBP-2 in a subset of ADNI subjects. 
Clinical Characteristics and Alzheimer’s Disease Risk 
 
Logistic regression was used to examine if plasma IGFBP-2 expression predicted an 
increased likelihood of being MCI or AD. The reference group was CN. The likelihood ratio 
statistic [Χ2=74.450, p<.001] indicated that higher IGFBP-2 levels predicted a higher Odds 
Ratio for being MCI or AD [Wald=9.938, β=3.003, p=0.002]. These results suggest that a per 
point increase in IGFBP-2 corresponded to a roughly 3 times likelihood of having some 
degree of clinically relevant memory impairment. No significant associations were shown 
with IGFBP-2 and MCI conversion.  No significant interaction was shown between IGFBP-2 
and APOE with regards to predicting an odds ratio for being MCI or AD. 
Global Cognition, Memory, Visual Spatial, and Executive Function 
 
Linear mixed models showed a non-significant main effect for IGFBP-2 on global 
indices including CDR-sob, ADAS-cog and MMSE. Among neuropsychological indices 
depicted in Figure 4.1, the number of APOE4 alleles modified how plasma IGFBP2 was 
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related to global cognition. Specifically, for CDR-sob, a IGFBP-2 * APOE interaction was 
significant (b±SE= -2.825±0.983, p=.034). Similarly for ADAS-cog, interaction analyses 
between IGFBP-2 * APOE were significant (b±SE= -6.607±3.469, p=.020), as well as for 
MMSE (b±SE= 1.407±0.699, p=.045). These results indicate that among subjects with 1 or 2 
APOE4 alleles, higher IGFBP-2 predicted better function on global assessments.  
For memory, higher IGFBP2 was also related to higher scores on the RAVLT Delay 
(b±SE= 1.652±0.482, p=<.001). No main effects or interactions with APOE4 were shown 
with respect to a derived memory factor. 
There were no IGFBP-2 by Baseline Diagnosis interactions. However, on an 
exploratory basis, when split by diagnosis, AD patients showed that IGFBP-2 was a 
significant predictor of worse scores on the constructional praxis portion of ADAS-cog, 
representing visual spatial abilities (b±SE= 1.189±0.580, p=.043). There were no significant 
associations between plasma IGFBP-2 and executive function. 
AD CSF Biomarkers and Markers of Inflammation 
 
Plasma IGFBP-2 was not associated with total tau, p-tau-181 or Aβ1-42. However, 
higher levels of IGFBP-2 were related to higher expression of IL-6 receptor (b±SE = 
0.071±0.029, F=5.940, p=0.15) and lower C-peptide (b±SE=-0.156±0.043, F=13.289, p<.001). 
No significant differences were seen with respect to IGFBP-2 and APOE4 or Baseline 
Diagnosis interactions. Importantly, as noted in Supplementary Text 4.1, CSF IGFBP-2 was 
conversely related to all AD biomarkers but not peripheral inflammation.  
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Glucose, Insulin and HOMA-IR 
 
Higher plasma IGFBP-2 was significantly associated with lower HOMA-IR (b=-.441, 
F=6.810, p=0.009) and insulin (b=-1.593, F=6.986, p=0.009), but not glucose (F=0.564, 
p=0.453).  Subsequent IGFBP-2 * APOE interactions were non significant. 150 of the 
participants met fasting blood glucose requirements for pre-diabetes diagnosis (between 
100 and 125 mg/dL), and 57 participants met fasting blood glucose requirements for 
diabetes diagnosis (>125 mg/dL). Both plasma and CSF IGFBP-2 were not predictive of 
whether or not a person met pre-diabetes or type 2 diabetes fasting blood glucose criteria. 
As noted in Supplementary Text 4.1, CSF IGFBP-2 was only related to higher glucose.  
Regional Grey Matter Volume 
 
Next, voxel-wise analysis was used to regress plasma IGFBP-2 concentrations against 
regional GM at baseline for 325 participants who had structural MRI data, demographic, 
and biological data. Higher plasma IGFBP-2 was related to less GM in a large cluster of 
voxels (k=128,608) across the right and left inferior parietal gyri, right frontal superior lobe, 
left postcentral gyrus, right cerebellum and right fusiform gyrus, with the maximum voxel 
located in the right frontal superior lobe (Figure 4.2; Supplementary Table 4.2). Smaller 
clusters included the cuneus, hippocampus, precuneus, and left and right superior 
prefrontal cortices. A similar pattern of results was found when regressing CSF IGFBP-2 
against regional GM. Higher CSF IGFBP-2 was related to less GM primarily spanning the left 
and right amygdala, parahippocampus and hippocampus, among 186 participants who had 
structural MRI data, demographic, and biological data (Supplementary Text 4.1).  
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Regional FDG Metabolism 
 
Higher plasma IGFBP-2 was related to less FDG glucose uptake in one cluster of 5419 
voxels primarily spanning the superior dorsolateral prefrontal cortex, among 266 
participants who had FDG data, demographic, and biological data (Figure 4.3).  
Genetic Analysis of IGFBP-2 
 
Linear regression in PLINK tested the additive genetic model of each SNP for 
association with cognitive scores while controlling for age, gender, and Baseline Diagnosis 
as covariates. Four variants in the IGFBP-2 locus on Chromosome 7 were nominally 
associated with worse cognitive function on the MMSE. Genotype distributions and odds 
ratios are listed in Table 4.2. RS4619 was nominally associated with MMSE (F=5.645, 
P=0.015), and the ADNI latent memory factor (F=6.115, P=0.013). Models comparing 
individual odds ratios and the average odds ratio between groups did not demonstrate 
significant differences between groups. Additionally, the relationship between these SNPs 
and baseline regional FDG and grey matter were assessed using voxel-wise analysis. Result 
maps indicated carriers of minor alleles in these SNPs showed less grey matter and FDG 
metabolism in a small region spanning the right frontal superior lobe. There was strong 
overlap between this result and what was found for IGFBP-2 gray matter and FDG result 
maps (Figure 4.4); however, the voxel wise result maps for individual SNPs marginally 
surpassed the ClusterSim statistical significance threshold of 462 voxels. 
Discussion 
 
In this study, we hypothesized that IGFBP-2 may serve as a useful biomarker for 
predicting AD outcomes. Importantly, higher IGFBP-2 corresponded to less grey matter in 
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AD-sensitive brain regions such as superior frontal gyrus and angular gyrus, and significantly 
less glucose uptake in the superior medial prefrontal cortex. Strikingly, for every point 
increase in IGFBP-2 levels, there was a 3 times increased risk of being diagnosed as MCI or 
AD when compared to CN. Curiously, however, higher IGFBP-2 corresponded to better 
cognitive performance in the RAVLT Delay, as well as global indices for APOE4 carriers only.  
These conflicting results may be due to a progression of insulin resistance, where the body 
is at first able to compensate for insulin resistance by releasing additional IGF to keep up 
with glucose demands of neuronal cells. Although much of glucose transport in the brain is 
insulin-independent via GLUT-1 and GLUT-3, insulin is necessary for GLUT-4 actions, which 
in rats has been detected in the cerebellum, olfactory bulb, and dentate gyrus of the 
hippocampus [28].  Although further research is necessary to translate these findings to 
humans, Craft et al. showed that intranasal insulin reduced progression of neuronal 
hypometabolism in individuals with MCI and AD, suggesting that insulin does play an 
important role in glucose uptake in the brain [29].  We hypothesize that central insulin 
resistance progresses to a point where GLUT-4 receptors are unable to respond to insulin 
and cells are delivered a suboptimal level of glucose. We suggest that the cognitive score 
results in our study are representative of the early compensatory response, which may in 
part be related to APOE4 status, while the grey matter, FDG, and diagnosis results are 
indicative of a post-compensatory state. In general, having one or more E4 alleles 
corresponded to higher IGFBP2 predicting better cognitive performance, whereas for non-
APOE4s either no association or a detrimental pattern was observed, such as for ADAS-cog. 
Additionally, previous research has shown that individuals who are APOE4 positive have 
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lower expression of insulin degrading enzyme, thus potentially amplifying the early 
cognitive benefits of higher IGFBP-2 levels [30]. 
IGF-1 appears to be a key modulator of IGFBP-2 associations with AD outcomes. 
Because IGFBP is fundamental in regulating IGF bioavailability, the two proteins are 
intertwined in determining insulin expression and glucose levels in the periphery and brain, 
which this report illustrates at least in plasma. IGF-1 importantly determines glucose and 
lipid handling in the brain, myelin expression, and remodeling after neuronal injury [1]. 
Mice that under-expressed IGF-1 showed an accumulation of Aβ plaques, which were 
subsequently decreased after infusing the mice with IGF-1 [31]. 
To validate IGFBP-2 as a useful biomarker of AD and central IR, higher plasma IGFBP-
2 corresponded with higher expression of plasma markers of inflammation including IL-6 
receptor and C-peptide. Previous research has shown many correlations between 
inflammation in the brain and neuronal damage [32]. Obesity and insulin resistance are also 
associated with higher levels of inflammatory biomarkers [33].  
We also compared and contrasted the utility of plasma IGFBP-2 to CSF IGFBP-2 for 
AD-related outcomes. CSF-based markers are often thought to provide better diagnostic 
accuracy in understanding the progression of diseases that cause cognitive impairment and 
dementia; however, collecting a CSF sample is more invasive. Our data indicate that when 
considering IGFBP-2, the plasma concentration was a better predictor of brain structure and 
cognition, while only CSF concentrations reflected CSF amyloid and tau. Future studies 
should take into account the differing clinical utility of blood-based and CSF biomarkers 
against the practicality of sample collection, in addition to their predictive utility of disease 
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progression. Improving how biomarkers are used in clinical trials will likely provide more 
precise diagnoses to patients with AD.  
Subsequently, we examined how IGFBP SNPs influenced AD-related outcomes. Since 
population stratification can result in erroneous genetic associations, we restricted our 
analyses to only subjects of Northern and Western European heritage. While the exact 
mechanism has yet to be revealed, our data show that genetic variation in IGFBP-related 
genes modified cognitive decline. This may be in part due to modifying IGF-1 regulation of 
glucose in the brain, ultimately increasing neuronal vulnerability to induce cognitive decline. 
Genetic variation negatively affecting IGFBP-2 signaling may decrease the protective effects 
that circulating IGFBP-2 exerts on cognition described above, whereby these SNPs may 
predispose individuals to develop AD. Previous large-scale genome-wide association studies 
(GWAS) examining genetic association with AD have not implicated SNPs at IGFBP loci 
because these variants commonly do not surpass genome wide significance of P < 1X10^-8. 
Performing targeted genomic association analysis in combination with neuroimaging 
analysis provides a unified approach to understand how genomic variation may contribute 
to AD symptoms.  
The limitations of this study should be addressed. This study included a modest 
sample size, where the exploratory nature of this study design would benefit from a larger 
sample. It is worth noting that these analyses did not show any significant correlations 
between plasma or CSF IGFBP-2 and MCI conversion. However, a larger sample size of 
individuals with MCI may be needed to see if IGFBP-2 can predict if an individual with MCI 
converts to AD. Furthermore, since this is a cross-sectional study using baseline data from 
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the ADNI cohort, it was beyond the scope of the project to determine the causal effects 
between IGFBP-2 on longitudinal CSF biomarkers and disease progression. Additionally, we 
could not correlate IGFBP-2 with all of the disease state associations throughout the 
literature such as gastric cancer or eating disorders because this was beyond the scope of 
ADNI’s mission.  Like all genetic studies, these results should be validated using additional 
independent and larger cohorts. Finally, other unrecognized cellular pathways, not related 
to neurodegeneration, may be disrupted that influence IGF-1 signaling and AD progression.  
Conclusion 
 
This study provides evidence that plasma IGFBP-2 is associated with AD risk, brain 
atrophy and less glucose metabolism in regions sub-serving memory and global cognitive 
function. We also demonstrated that plasma IGFBP-2 served as a more comprehensive 
predictor of AD-related outcomes than CSF IGFBP-2. These results illustrate the potential 
that integration of genomic, biologic and neuroimaging data may lead to identification of 
novel targets for treatment of AD while improving the overall understanding of potential 
mechanisms underlying the pathophysiology of AD. In conclusion, insulin signaling 
mechanisms such as IGFBP-2 may be important for future therapeutics to target via genetic 
modification or regulating circulating IGFBP-2 to delay the onset of AD by improving neural 
metabolism and cognitive function. 
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Tables and Figures 
 
Table 4.1. Demographic Data for Subjects with Plasma IGFBP-2 
  CN (N=58) MCI (N=396) AD (N=112) 
Age 76.27 ± 5.73 74.91 ± 7.49 75.23 ± 8.39 
Education (years) 15.67 ± 2.78 15.64 ± 3.0 15.1 ± 3.2 
Sex % Female 48 35 42 
% APOE 4 carriers *** 9% 49% 64% 
Plasma IGFBP2 (ng/mL) *** 1.88 ± 0.20 1.99 ± 0.23 1.91 ± 0.12 
C Peptide (ng/mL) 0.37 ± 0.21 0.39 ± 0.21 0.36 ± 0.18 
IL-6 Receptor (ng/mL)* 1.51 ± 0.12 1.46 ± 0.14 1.47 ± 0.11 
Glucose (mg/dL) 102.33 ± 23.47 101.42 ± 27.25 99.06 ± 22.48 
Insulin (uIU/mL) 3.00 ± 2.34 2.64 ± 2.73 2.38 ± 1.43 
HOMA-IR 0.82 ± 0.80 0.68 ± 0.75 0.59 ± 0.39 
CSF Total Tau (pg/mL)*** 63.62 ± 21.76 102.66 ± 59.81 120.30 ± 56.33 
Ptau (pg/mL)*** 21.07 ± 8.43 36.19 ± 19.28 41.92 ± 19.90 
Abeta 42 (pg/mL)*** 250.85 ± 21.08 163.97 ± 53.15 142.69 ± 39.15 
CDR-SOB*** 0.03 ± 0.11 1.61 ± 0.88 4.31 ± 1.61 
MMSE*** 28.93 ± 1.16 27.02 ± 1.78 23.59 ± 1.96 
Immediate RAVLT*** 40.98 ± 7.19 30.73 ± 9.05 23.54 ± 7.42 
Delayed RAVLT* 3.73 ± 3.13 4.72 ± 2.25 4.47 ± 1.94 
ADAS-COG*** 6.37 ± 2.76 11.52 ± 4.38 18.27 ± 6.37 
ADNI_MEM Score*** 0.46 ± 0.72 0.03 ± 1.04 -0.35 ± 0.85 
Executive Function*** 0.71 ± 0.58 -0.03 ± 0.78 -0.93 ± 0.83 
  
Values are mean ± SD, * indicates ANOVA p<0.05; **indicates p<0.01; *** indicates ANOVA 
or chi-square p<0.001. Chi-square analyses were conducted to examine differences 
between gender and APOE4 status.   The ADNI memory factor values are Z-scored with 
mean 0 and a standard deviation of 1, based on the 810 subjects with baseline memory 
data [20]. 
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Table 4.2. Association of IGFBP-2 SNPs with Mini-Mental Status Exam (MMSE) scores and 
the ADNI Memory composite score 
 
 
Beta values represent the difference in the predicted value of either MMSE or the ADNI 
memory factor based on an increase from no risk allele, one risk allele, or two risk alleles. 
 
 
 
 
 
 
 
 
 
  
 MMSE  ADNI Memory Factor  
SNP Common Allele 
Effect 
Allele Beta 
Beta P 
value 
Common 
Allele Effect Allele Beta 
Beta P 
value 
rs4619  
29.1 ± 1.55 24.9 ± 2.02 -0.32 P = 0.089 1.01 ± 0.59 −0.14 ± 0.64 -0.12 P = 0.047 
AA vs GA + GG 
rs138105891  
28.5 ± 1.31 25.4 ± 0.57 -0.21 P = 0.044 0.95 ± 0.44 0.33 ± 0.39 -0.30 P = 0.068 
AA vs GA + GG 
rs41258845  
29.2 ± 1.17 25.6 ± 1.02 -0.34 P = 0.199 1.03 ± 0.67 −0.04 ± 0.77 -0.11 P = 0.041 
CC vs GC + GG 
rs1065782  
27.2 ± 1.75 24.5 ± 1.09 -0.17 P = 0.441 1.10 ± 0.48 −0.02 ± 0.58 -0.22 P = 0.052 
 GG vs GA + AA 
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Supplementary Table 4.1: Demographic Data for Subjects with CSF IGFBP-2 
 CN (N=45) MCI (N=134) AD (N=66) 
Age 76.7 ± 5.9 75.7 ± 7.4 76.0 ± 7.5 
Education 15.5 ± 2.9 16.0 ± 3.0 15.1 ± 3.0 
Sex % Female* 49% 31% 44% 
% APOE 4 carriers *** 9% 49% 67% 
CSF IGFBP2 Peptide 23.77 ± 0.3 0 23.78 ± 0.31 23.82 ± 0.37 
ADNI_MEM Score*** 0.83 ± 0.49 -0.15 ± 0.53 -0.84 ± 0.58 
 
Values are mean ± SD, * Indicates ANOVA P<0.05, *** = P<0.001. The ADNI memory factor 
values are Z-scored with mean 0 and a standard deviation of 1, based on the 810 subjects 
with baseline memory data. 
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Supplementary Table 4.2: Main effects of serum IGFBP-2 on regional grey matter volume 
 
Location T value X, Y, Z Cluster size (voxels) 
Frontal Superior (R)  5.27 -15, 31, 55 128608 
Angular (R, L) 5.25 34, -58, 51  
Parietal Inferior (L) 5.07 -54, -27, 45  
Frontal Middle (R) 5.04 44, 15, 46  
Precentral Gyrus (R) 4.96 48, 6, 38  
Supplemental Motor Area (L) 4.88 -7, 14, 67  
Parahippocampal (R) 4.81 21, 4, -34  
Precuneus (R) 4.77 3, -58, 51  
Hippocampus (L) 4.59 -28, -39, 4  
Anterior Cingulum 4.51 -5, 39, 4  
Amygdala (L) 4.43 -22, -3, -13  
Parahippocampus (R) 4.33 17, -32, -13  
 Frontal Inferior  (R) 4.32 40, 8, 28  
Cuneus (L) 4.21 -3, -81, 34  
Postcentral Gyrus (R) 4.14 36, -34, 50  
Frontal Superior (L)  4.21 -12, 57, 26 1206 
Frontal Superior Medial (L) 4.73 -4, 28, 46  
 
This table depicts regions where all subjects had less predicted gray matter volume as 
IGFBP-2 increased. The highest t value for a given cluster of significant, contiguous voxels is 
shown. For clusters that extended over more than 15 mm, the highest t value in those areas 
is indicated. Coordinates are in MNI atlas space. Brains are oriented in neurological space. 
 
L left hemisphere, R right hemisphere 
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Figure 4.1: Cognitive scores and IGFBP-2 analyses. The association between plasma IGFBP-2 
and the Clinical Dementia Rating sum of boxes (CDR-sob), Mini-Mental Status Exam 
(MMSE), Rey Auditory Verbal Learning Test (RAVLT), AD Assessment Schedule - Cognition 
(ADAS-Cog). “Blue circle” indicates 0 APOE4 alleles, “green triangle” indicate 1 APOE4 allele, 
and “red star” indicates 2 APOE4 alleles. 
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Figure 4.2: Brain areas showing less grey matter corresponding to higher plasma IGFBP-2. 
The graph depicts the relationship at a sub-maximal voxel in dorsal prefrontal cortex. 
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Figure 4.3: Brain areas showing less FDG metabolism corresponding to increased plasma 
IGFBP-2. The graph depicts the relationship at a sub-maximal voxel in the dorsal prefrontal 
cortex. 
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Figure 4.4: Brain areas showing overlap between either the GM or FDG and IGFBP2 result 
maps and the result map of the strongest SNP association for GM or FDG.  
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Supplementary Text 4.1 – CSF IGFBP 2 and Outcomes 
 
Global, Memory, and Visual Spatial Indices 
 
No significant differences were shown with regards to cognitive indices and CSF 
IGFBP-2. However, there was a significant negative CSF IGFBP-2 * Age interaction with 
executive function (F= 6.417, p=0.012), indicating that among older subjects, higher CSF 
IGFBP-2 was related to worse performance. 
For visual spatial assessment, there was an APOE Status * IGFBP-2 interaction for the 
clock drawing test total score (F=4.912, p=.008) and the construction stimulus score of the 
MMSE exam (F=4.653, p=.010). Among APOE4 carriers, higher IGFBP-2 was related to lower 
scores. Similarly, for the clock drawing test, an Age * IGFBP-2 interaction (F=5.806, p=0.017) 
showed that among older subjects, higher IGFBP-2 predicted a lower total score.  
AD CSF Biomarkers and Markers of Inflammation 
 
Higher CSF IGFBP-2 concentrations were related to higher levels of CSF tau 
(F=17.134, p<.001), phosphorylated tau (F=4.121, p=.044), and CSF Aβ1-42 (F=5.265, 
p=.023). CSF IGFBP-2 was not related to any of the biomarkers of inflammation. 
Glucose, Insulin and HOMA-IR 
 
CSF IGFBP-2 was not associated with HOMA-IR (F=0.127, P=0.143) or with insulin 
(F=0.753, P=0.231); however, it was significantly related to higher glucose (F=9.554, 
P=0.002). 
Regional Grey Matter Volume 
 
CSF IGFBP-2 was regressed against regional GM at baseline using VBM. Higher CSF 
IGFBP-2 was related to less GM in two clusters (9917 and 15455 voxels) spanning areas 
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similar to the plasma results, as well as the left and right inferior parietal, cerebellum and 
right fusiform gyrus, with the maximum voxel located in the right frontal superior lobe. 
Regional FDG Uptake 
 
CSF IGFBP-2 showed no significant associations with FDG metabolism among the 126 
participants who had FDG data, demographic, and biological data. 
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 IS CSF SOD1 A BIOMARKER OF TAU BUT NOT AMYLOID INDUCED 
NEURODEGENERATION IN ALZHEIMER’S DISEASE? 
 
Modified from a manuscript published in Antioxidants and Redox Signaling 
Kelsey E. McLimansa*; Bridget E. Clarka*†; Alexandra Plagmana; Colleen Pappasa; Brandon 
Klinedinstb; Vellareddy Anatharamc; Anumantha Kanthasamyc; Auriel A. Willettea,b,c,d,e, for 
the Alzheimer’s Disease Neuroimaging Initiative‡ 
aDepartment of Food Science and Human Nutrition, Iowa State University, Ames, IA 
bNeuroscience Graduate Program, Iowa State University, Ames, IA 
cDepartment of Biomedical Sciences, Iowa State University, Ames, IA 
dDepartment of Psychology, Iowa State University, Ames, IA 
eDepartment of Neurology, University of Iowa, Iowa City, IA  
 
Reprinted from Antioxidants and Redox Signaling, McLimans KE, Clark BE, Plagman A, 
PappasC, B. Klinedinst, Anatharam V; Kanthasamy A; Willette AA. Is CSF SOD1 a Biomarker 
of Tau but not Amyloid Induced Neurodegeneration in Alzheimer’s Disease? In press. 
 
Abstract 
 
 Copper/zinc superoxide dismutase (SOD1) scavenges free radicals that may 
otherwise damage brain parenchyma. Impaired SOD1 activity drives AD neuropathology in 
animal models and post-mortem AD brains. Yet, it is unknown how CSF SOD1 is related in 
vivo to AD-relevant cognitive, neuroimaging, and CSF neurotoxic factors, and what potential 
                                                        
* Shared first authorship 
† Permanent address: Department of Nutrition Science & Dietetics, Syracuse University, Syracuse, NY 
‡ Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and 
implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A 
complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
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mechanisms underlie these associations. We found that higher CSF SOD1 correlated with 
better global cognition scores, yet less gray matter (GM) and glucose metabolism in AD-
sensitive parietal and frontal regions. Higher CSF SOD1 was also associated with more CSF 
total tau and phosphorylated tau-181, but not beta-amyloid (Aβ) 1-42. Through mediation 
analyses, higher total tau largely mitigated higher CSF SOD1 and better global cognition 
associations, and it fully accounted for less predicted regional GM but not glucose 
metabolism. Among participants who developed AD over 2 years or had AD at baseline, 
higher CSF SOD1 was initially related to more regional GM. This association became non-
significant with full mediation via higher CSF total tau, whereby higher CSF SOD1 predicted 
more total tau and in turn less GM. Our observations lead to the hypothesis that SOD1 
antioxidation reflects tau but not amyloid accumulation, which may lead to prooxidant-
based neurodegeneration and cognitive dysfunction. 
Introduction 
 
Oxidative stress is thought to play a major role in the pathophysiology of AD.  
Particularly, brain proteins and lipids are susceptible to oxidative damage.  It is unclear if the 
oxidative damage seen in AD is a result of the disease process or causes neurological 
decline. SOD is a ubiquitous enzyme that protects against ROS formed during aerobic 
respiration(9). Specifically, SOD is an antioxidant enzyme that catalyzes the oxidation-
reduction reaction of the superoxide anion (O2•−) into oxygen (O2) and hydrogen peroxide 
(H2O2).  SOD consists of three isoenzymes: copper/zinc SOD, or SOD1, localized 
predominantly to the cytosol; manganese SOD, or SOD2, within mitochondria; and 
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extracellular SOD, or SOD3. Changes in SOD levels can cause excess ROS in cells, leading to 
altered intracellular and mitochondrial metabolism, as well as DNA and vascular damage.   
SOD1 has been examined in AD for its role in preserving neural integrity and 
memory performance.  Increased SOD1 levels are seen in the pyramidal neurons of AD 
patients compared to controls(3). For hippocampal cells of AD patients and related 
transgenic models, SOD1 overexpression downregulates Aβ-induced oxidative stress, using 
a non-oxidized versus oxidized glutathione ratio as a marker(2). Further, co-expression of 
SOD1 in APP transgenic mice blocks endothelial dysfunction that gives rise to hypoperfusion 
often seen in AD(5). SOD1-deficient Tg2576 mice, meanwhile, show increased Aβ plaque 
formation, neuroinflammation, tau phosphorylation, and memory decline(6).  
In this study, CSF SOD1 data collected by the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) in 287 aged adults was examined with respect to CSF Aβ1-42 and tau 
pathology markers, brain atrophy and glucose uptake, and cognitive performance. 
Innovation 
 
 Despite SOD1’s protective role for memory and neuropathology seen in post-
mortem AD brains and AD transgenic models, it is unknown how SOD1 is related in vivo to 
cognition, brain, and CSF toxic marker outcomes across the AD spectrum. Via mediation, we 
found that higher CSF total tau and to a lesser extent phosphorylated tau, but not CSF Aβ1-
42, largely mitigated “beneficial” global cognition associations. Total tau fully mediated 
SOD1 predicted atrophy in AD-sensitive regions. We hypothesize that CSF SOD1 is an in vivo 
biomarker of tau but not amyloid related neurodegeneration in AD, where tau’s causal role 
remains unclear.  
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Results 
Data Summary 
 
Clinical and demographic data on 287 ADNI participants are presented in Table 5.1. 
There were no differences based on years of education, age, or CSF SOD levels at baseline 
between CU, MCI or AD subjects. As expected for this ADNI sub-population, the percentage 
of APOE4 carriers increased stepwise from CU to AD. There was also significantly fewer 
women in the MCI and AD relative to CU groups.  
Global Cognition and Memory 
 
Broadly, we observed that higher CSF SOD1 was related to “better” scores for global 
cognition but not sub-domain tests. Specifically, for CDR-sob, higher CSF SOD-1 was 
significantly associated with better scores (b±SE= -0.625±0.285, p<0.05). Similarly, SOD1 
was related to better ADAS-cog11 (b±SE= -2.768±1.033, p<0.01) and MMSE scores (b±SE= 
0.973±0.397, p<0.05). SOD1 main effects, or interactions with APOE4 status or baseline 
clinical diagnosis, were non-significant for memory and executive function factors, as well as 
RAVLT indices. 
AD CSF Biomarkers  
 
CSF SOD1 was significantly related to higher levels of total tau (b±SE= 81.666±5.986, 
p<.001) and p-tau-181 (b±SE= 18.440±2.253, p<.001) (Figure 5.1). No significant differences 
were seen with respect to SOD1 and CSF Aβ1-42.  
Regional FDG Metabolism 
 
Next, voxel-wise analysis was used to regress CSF SOD1 levels against regional FDG 
uptake, an index of glucose metabolism, at baseline. Higher CSF SOD1 was significantly 
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associated with less FDG (p<.05, FWE corrected) in a large cluster with the maximum in left 
supplementary motor area (Figure 5.2, “blue” cluster; Table 5.2). This cluster bilaterally 
spanned superior medial frontal gyrus, mid- and posterior cingulate gyri, pre- and post-
central gyri, precuneus, lobulo-limbic transitional gyrus, as well as left angular gyrus. 
Smaller clusters encompassed anterior cerebellum or pre- and post-central gyri. 
Regional Grey Matter Volume 
 
 Voxel-wise analysis was also used to examine how CSF SOD1 concentrations were 
associated with regional GM at baseline. Higher CSF SOD1 was related to less GM (p<.05, 
FWE corrected) in a large cluster (Figure 5.2, “green” cluster; Table 5.3), with the maximally 
significant voxel in left supplementary motor area. This cluster bilaterally encompassed 
precuneus and pre- and post-central gyri, as well as left lobulo-limbic transitional 
gyrus/paracentral lobule, superior parietal gyrus, and superior frontal gyrus (Figure 5.2; 
Table 5.3).  
Preacher-Hayes Mediation of SOD1 for Memory, GM, and FDG-PET Outcomes 
 
Lastly, Preacher-Hayes mediation analyses were used to separately determine if CSF 
total tau, p-tau-181, or Aβ1-42, acted as mediator for the associations between SOD1 and 
global cognition, GM, and FDG outcomes. In summary, CSF total tau or to a lesser extent p-
tau-181, but not CSF Aβ1-42, partially or fully mediated SOD1 associations. 
 For the higher SOD1 and better MMSE score association (direct effect β±SE = 2.980 ± 
0.441, p<.001), higher total tau acted as a partial mediator, decreasing the statistical effect 
of SOD1 on MMSE by 67.6% (indirect effect β±SE = -2.014±0.358, p<.01) (Figure 5.3A). In a 
separate model, P-tau-181 also showed significant, albeit weaker partial mediation of the 
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SOD1 and MMSE association, decreasing the statistical effect by 51.5% (direct effect β±SE = 
2.002 ± 0.407, p<.001; indirect effect β±SE = -1.028 ± 0.237, p<.01). Similar associations 
were seen for CDR-sob and ADAS-cog11. 
For the higher CSF SOD1 and less regional GM association, we focused on precuneus 
because hypometabolism and atrophy there are imaging markers of progression from 
preclinical AD to AD.  As shown in Figure 5.1, SOD1 originally predicted less precuneus GM 
to a moderate degree (β±SE = -0.064±0.0142, p<.001). CSF total tau fully mediated this 
relationship (indirect effect: β±SE = -0.035 ± 0.015, p<.05) (Figure 5.3B), where the SOD1-
GM direct effect was non-significant (β±SE = -0.047±0.024, p>.05). In a separate model, P-
tau-181 partially mediated SOD1 and precuneus GM associations, increasing the degree of 
association by 35% (direct effect: β±SE = -0.049±0.016, p<.05; indirect effect: β±SE = -
0.017±0.008, p<.05). Total tau and p-tau-181 did not mediate associations between higher 
CSF SOD1 and less baseline regional FDG uptake. 
 To explore if AD onset and progression drove these GM mediation results, we re-ran 
models only with MCI participants who converted to AD within 24 months and participants 
classified as AD at baseline. As shown in Figure 5.4, higher CSF SOD1 was related to more 
regional GM in precuneus (direct effect: β±SE = 0.106 ± 0.034, p<.01). Higher total tau levels 
fully mediated this association via suppression, decreasing the statistical effect on GM by 
90% (indirect effect: β ± SE = -0.094±0.027, p<.01) and rendering the total effect association 
between CSF SOD1 and more regional GM non-significant. Recall that for voxel-wise 
analyses including all participants (see Figure 5.3B), higher SOD-1 predicted less GM that 
was also fully mediated by higher CSF total tau.  
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Discussion 
 
 Progressive pro-oxidant damage has been associated with AD hallmarks such as tau 
and amyloid neuropathology, memory decline, and less neural integrity in AD-sensitive 
regions.  In this study, we observed across the AD spectrum that more CSF SOD1 was 
related to more CSF tau species but not Aβ1-42. CSF total tau via mediation suppressed 
“beneficial” SOD1 associations with cognition and fully accounted for less predicted GM, 
but not glucose uptake, in AD-sensitive parietal and frontal regions. Even so, this leads to 
the further question of whether total tau induces pro-oxidation or reflects a specific pro-
oxidative process separate from Aβ1-42. 
In AD rodent models, higher SOD1 expression generally appears to induce protection 
in brain (1,5,6) and preserve cognition (4).  We observed that higher CSF SOD1 
corresponded to better global cognitive function based on CDR-sob, ADAS-cog11 and MMSE 
in all participants. This is consistent with a study among aged mice that overexpressed 
extracellular SOD (i.e., SOD1), which showed improved motor learning and decreased age-
related decline in spatial memory as compared to controls(4).  The authors also illustrated 
an improvement in long-term potentiation, a molecular process underlying learning and 
memory, in the mice overexpressing extracellular SOD. While our observations are 
correlational and mediation with this data cannot be used to make causal interpretations, it 
was nonetheless interesting that higher total tau, but not CSF Aβ1-42, reflected drastic 
mitigation but not erasure of CSF SOD1 associations with global cognition.  
 Here, regardless of clinical diagnosis, higher SOD1 levels across all participants were 
strongly correlated with more CSF total tau and p-tau-181 levels but not Aβ1-42.  This led to 
 111 
our hypothesis that progressive neurodegeneration reflecting more tau deposition might 
induce more SOD1 to minimize free radical damage. These findings parallel Winer and 
colleagues, who showed a significant positive correlation between CSF SOD1 levels and both 
tau and phosphorylated tau in aged adults with AD (8). They also observed weak CSF SOD1 
associations with CSF Aβ1-42 across all diagnostic groups and no associations among any of 
the sub-groups (8), which is in line with our observing no such relationships in this study. 
We hypothesize that SOD1 activity may reduce tau-related neurodegeneration in areas 
affected later in the disease, where other antioxidant factors may regulate pro-oxidant 
damage reflecting amyloidosis. Alternatively, since tau is indicative of neuronal injury, and 
oxidative stress can cause cell death, tau and SOD-1 may track neurodegeneration during 
AD onset and progression better than Aβ1-42. 
Indeed, for regional GM and FDG metabolism, CSF SOD1 was related to less GM and 
glucose metabolism in precuneus, posterior cingulate gyrus, paracentral lobule, and frontal 
gyri. Our mediation analyses suggest that tau accumulation reflecting progressive pro-
oxidant damage may affect atrophy in these areas, which in part distinguish AD onset and 
progression. Indeed, CSF SOD1 no longer significantly predicted more GM in participants 
with AD onset or AD at baseline after total tau mediation. It is our hypothesis that SOD 
production may thus be futile in controlling free radical levels once a participant is on a 
trajectory for AD onset and progression. This phenomenon may extend beyond neural 
parenchyma. For example, Erythrocyte SOD activity was significantly higher in a group of 27 
AD participants compared to controls; the SOD levels in the AD and control participants 
were also positively correlated with serum malondialdehyde levels, which is a marker of 
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oxidative stress, suggesting that the body is producing SOD in an attempt to reduce 
oxidative stress levels(8).   
We should note several limitations with this study. First, all analyses were 
correlational, and while mediation analyses suggested more total tau largely drove SOD1 
associations, it remains unclear if tau accumulation induces redox imbalance or serves an 
antioxidant function to reduce pro-oxidative damage. Therefore, experimental paradigms 
are needed to test if AD human tau neurons in transplanted in AD or control rodent parietal 
and frontal regions induce pro- or anti-oxidation, and how CSF SOD1 application affects 
neurite integrity with or without tau present. Dietary recall was also not collected in ADNI 
participants, which would have been helpful to assess the link between diets that induce 
oxidative stress and SOD1 expression in the brain.  Participant CSF samples were only 
assayed at baseline, so we were unable to longitudinally examine CSF SOD1 and variation 
over time in AD outcomes.  Lastly, plasma SOD1 that was assayed in ADNI1 did not pass 
quality control measures, which did not allow us to see if similar associations occurred in 
the periphery.  
In summary, we observed that CSF SOD1 has strong associations with total tau and 
p-tau-181 in CSF, global cognition, and regional GM and glucose metabolism, all of which 
have been linked with AD etiopathogenesis. We observed that CSF SOD1 is associated with 
better global cognition, yet less GM and glucose uptake in parietal and frontal areas that are 
sensitive to AD-related changes. We noted that higher total tau appears to partially or fully 
mediate these associations, nearly mitigating the statistical effect of more SOD1 on better 
MMSE scores and less regional GM volume. Because of these novel findings, we 
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hypothesize that CSF SOD1 may simultaneously be related to the degree of AD-related 
neurodegeneration seen in the brain specific to tau accumulation, but also reflect the 
degree of free radical scavenging as a compensatory mechanism. Future work should 
examine if CSF SOD1 levels are related to regional tau deposition and track progressive 
accumulation across the AD spectrum; additionally, forthcoming research should determine 
the utility of peripheral SOD1 as a biomarker for AD outcomes. 
Notes 
Participants 
 
Data from middle-aged to aged adults were obtained from the ADNI database 
(http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, 
led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), 
other biological markers, and clinical and neuropsychological assessment can be combined 
to measure the progression of MCI and early AD. For up-to-date information, see 
http://www.adni-info.org. Written informed consent was obtained from all ADNI 
participants at their respective ADNI sites. The ADNI protocol was approved by site-specific 
institutional review boards. Baseline CSF data for SOD1 was available for 287 subjects: 86 
CU individuals, 135 MCI individuals, and 66 individuals with AD.  
Participants with MCI met the following diagnostic criteria: 1) memory complaint 
identified by the participant or their study partner; 2) abnormal memory as assessed by the 
Logical Memory II subscale from the Wechsler Memory Scale- Revised; 3) Mini-Mental State 
Exam (MMSE) score between 24 and 30; 4) Clinical dementia rating of 0.5; 5) Deficits not 
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severe enough for the participant to be diagnosed with Alzheimer’s disease by the site 
physician at screening. Participants with AD met similar criteria, however, were required to 
have an MMSE score between 20 and 26, a clinical dementia rating of 0.5 or 1.0, and 
NINCDS/ADRDA criteria for probable AD. 
Mass Spectrometry and SOD1 
 
Data were downloaded from the Biomarkers Consortium CSF Proteomics MRM 
dataset. The ADNI Biomarkers Consortium Project investigated the extent to which selected 
peptides, measured with mass spectrometry, could discriminate among disease states. 
Briefly, Multiple Reaction Monitoring-MS (MRMMS) was used for targeted quantitation of 
567 peptides representing 221 proteins in a single run (Caprion Proteome Inc., Montreal, 
QC, Canada). Analyses for this report focused on cytosolic SOD1 levels, which were assayed 
in the CSF multiplex panel as reflected by the peptide GDGPVQGIINFEQK.  
APOE Genotype 
 
The ADNI Biomarker Core at the University of Pennsylvania conducted APOE ε4 
genotyping. We characterized participants as having zero APOE4 alleles, one APOE4 allele, 
or two APOE ε4 alleles. Analyses did not differ when discriminating APOE4 carriage vs. non-
carriage.  
Amyloid and Tau CSF Biomarkers 
 
CSF sample collection, processing, and quality control of p-tau-181, total tau, and 
Aβ1-42 are described in the ADNI1 protocol manual (http://adni.loni.usc.edu/).  Briefly, CSF 
samples were analyzed using INNO-BIA Alz Bio3 immunoassay reagents with the Luminex 
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platform.  Statistical modeling was completed to confirm reliability of results across seven 
laboratories before implementation with ADNI. 
Neuropsychological Assessment 
 
ADNI utilizes an extensive battery of assessments to examine cognitive functioning 
with particular emphasis on domains relevant to AD. A full description is available at 
http://www.adni-info.org/Scientists/CognitiveTesting.aspx. All subjects underwent clinical 
and neuropsychological assessment at the time of scan acquisition. Neuropsychological 
assessments included: The Clinical Dementia Rating sum of boxes (CDR-sob), Mini-Mental 
Status Exam (MMSE), Auditory Verbal Learning Test (RAVLT) and AD Assessment Schedule - 
Cognition (ADAS-Cog). A composite memory score encompassing the RAVLT, ADAS-COG, 
MMSE, and Logical Memory assessments was also utilized. This composite memory score 
was used in formal analyses to represent global memory among subjects. 
Magnetic Resonance Imaging (MRI) Acquisition and Pre-Processing 
 
T1-weighted MRI scans were acquired within 10-14 days of the screening visit 
following a back-to-back 3D magnetization prepared rapid gradient echo (MP-RAGE) 
scanning protocol described in the ADNI MRI Technical Procedures Manual 
(https://adni.loni.usc.edu). The SPM12 “New Segmentation” tool was used to extract 
modulated gray matter (GM) volume maps. Maps were smoothed with an 8mm Gaussian 
kernel and then used for all voxel-wise analyses.  
FDG-PET 
 
Briefly, 185 MBq of [18-153-F]-FDG was injected intravenously. After 30 minutes, six 
5-minute frames were acquired. Frames of each baseline image series were co-registered to 
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the first frame and combined into dynamic image sets. Each set was averaged, reoriented to 
a standard 160 x 160 x 96 voxel spatial matrix of resliced 1.5 mm3 voxels, normalized for 
intensity, and smoothed with an 8 mm FWHM kernel. In order to derive the standardized 
uptake value ratio (SUVR), pixel intensity was normalized according to the pons since it 
demonstrates preserved glucose metabolism in AD. Normalization to the pons removed 
inter-individual tracer metabolism variability. The Montreal Neurological Institute (MNI) 
template space was used to spatially normalize images using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). 
Statistical Analysis 
 
All analyses were conducted using SPSS 25 (IBM Corp., Armonk, NY) or SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). For non-MRI or FDG analyses, linear 
mixed regression models tested the main effects of CSF SOD1 on outcomes including 
neuropsychological performance and AD CSF biomarkers including Aβ1-42, total tau and p-
tau-181. Main effects and interactions with APOE4 allele load were separately tested in a 
single model. Covariates included age at baseline, BMI, sex, and baseline clinical diagnosis.  
Participant years of education was also included as a covariate for models with cognitive 
tests as an outcome of interest.  Baseline diagnosis was not used as a covariate for models 
with cognitive tests as an outcome of interest to avoid multicollinearity.  Preacher Hayes 
mediation analyses were conducted in SPSS 25 using PROCESS v3.3.  Non-significant 
covariates were removed from final models for model parsimony. 
For voxel-wise analysis, 2nd-level mixed models tested main effects of SOD1 on 
regional GM volume and FDG, controlling for age, sex, BMI, APOE4 status, and baseline 
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clinical diagnosis. Voxel and cluster statistical thresholds were set at p<.005 (uncorrected) 
and p<.05 (FWE corrected) respectively. Results were considered significant at the cluster 
level. As described previously(7), in order to further reduce type 1 error, we utilized a GM 
threshold of 0.2 to ensure that voxels with <20% likelihood of being GM were not analyzed. 
For GM, Monte Carlo simulations in ClusterSim 
(http://afni.nimh.nih.gov/afni/doc/manual/3dClustSim) were used to estimate that 462 
contiguous voxels were needed for such a cluster to occur at FWE p < 0.05. For FDG voxel-
wise analyses, Monte Carlo simulations were used to estimate that 224 contiguous voxels 
were needed for such a cluster to occur at FWE p < 0.05.   
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Tables and Figures 
 
Table 5.1: Demographic data for ADNI subjects with CSF SOD1 
 
 CU (N=86) MCI (N=135) AD (N=66) 
Age (years) 75.70 ± 5.54 74.67 ± 7.32 75.04 ± 7.62 
Education (years) 15.64 ± 2.97 16.02 ± 2.97 15.06 ± 2.93 
Sex (% female)* 48.8% 32.6% 43.9% 
BMI (kg/m2) 26.54 ± 3.84 25.98 ± 3.77 26.36 ± 4.28 
APOE4 carriage (%)*** 24.4% 52.6% 71.2% 
CSF SOD (AU) 21.46 ± 0.34 21.49 ± 0.37 21.42 ± 0.39 
CDR-sob (score)*** 0.02 ± 0.11 1.54 ± 0.86 4.37 ± 1.54 
ADAS-cog11 (score)*** 6.05 ± 2.90 11.73 ± 4.33 18.86 ± 6.73 
EF factor (Z-score)*** 0.66 ± 0.62 -0.08 ± 0.73 -1.02 ± 0.81 
Memory factor (Z-score)*** 0.98 ± 0.50 -0.15 ± 0.57 -0.90 ± 0.56 
MMSE (score)*** 29.05 ± 1.02 26.92 ± 1.74 23.50 ± 1.83 
 
Values are mean ± SD unless otherwise stated. *,***= Chi-square p < .05, < .001.   
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Table 5.2: Negative main effects of SOD on FDG metabolism  
 
Location T value X, Y, Z Cluster size (voxels) 
Mid Cingulate Gyrus (R) 5.31 4, -2, 44 5214 
Precuneus (R) 4.72 2, -48, 44  
Mid Cingulate Gyrus (R) 4.25 4, -20, 48  
Cerebellum 3.28 -6, -58, -14 263 
Cerebellum 3.18 -8, -64, -22  
Precentral Gyrus (R) 3.00 34, -16, 68 282 
Postcentral Gyrus (R) 2.83 38, -36, 70  
 
This table depicts regions where all subjects had less predicted FDG metabolism as a 
function of more CSF SOD1. The highest t value for a given cluster of significant, contiguous 
voxels is shown. For clusters that extended over more than 15 mm, the highest sub-maxima 
t values in those areas are indicated. Coordinates are in MNI atlas space. Brains are oriented 
in neurological space. 
L left hemisphere, R right hemisphere 
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Table 5.3: Negative main effects of SOD on regional grey matter volume 
 
Location T value X, Y, Z Cluster size (voxels) 
Supplementary Motor Area (L) 4.57 -9, -10, 78 3855 
Precuneus (L) 4.33 -10, -50, 72  
Paracentral Lobule (R) 4.23 2, -28, 69  
 
This table depicts regions where all subjects had less predicted grey matter as a function of 
more CSF SOD1. The highest t value for a given cluster of significant, contiguous voxels is 
shown. For clusters that extended over more than 15 mm, the highest sub-maxima t values 
in those areas are indicated. Coordinates are in MNI atlas space. Brains are oriented in 
neurological space. 
L left hemisphere, R right hemisphere 
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Figure 5.1: The association between higher CSF SOD1 and higher covariate-adjusted CSF 
total tau (A) and p-tau-181 (B) values. 
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Figure 5.2: Brain areas showing less FDG metabolism (“blue”) and GM (“green”) as a function 
of more CSF SOD1.  Numbers below each brain slice represent the sagittal MNI coordinates 
of the slice.  Overlapping areas showing both less FDG metabolism and GM are teal. The GM 
graph depicts the relationship at the maximal voxel in the left supplementary motor area (-
9, -10.5, 78) and the FDG graph depicts the relationship at the maximal voxel in middle 
cingulate gyrus (4, -2, 44).  To see this illustration in color, the reader is referred to the 
online version of this article at www.liebertpub.com/ars.  
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Figure 5.3: Preacher-Hayes mediation of CSF SOD-1, total tau, and MMSE scores at baseline 
(A). Preacher-Hayes mediation of CSF SOD1, CSF total tau, and regional GM volume in left 
precuneus in a sub-maximum voxel (-10.5, -49.5, 72) (B). 
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Figure 5.4: Preacher-Hayes mediation of CSF SOD1, total tau and regional GM volume in left 
precuneus in a sub-maximum voxel (-10.5, -49.5, 72) among participants with MCI who 
converted to AD within 24 months and AD participants diagnosed at baseline. 
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Abstract  
B-vitamin supplementation has been shown to reduce brain atrophy in cognitively 
impaired participants. Epidemiological studies, however, show mixed findings for higher 
serum B12 and both cognitive and regional volume outcomes.  No studies to date have 
                                                        
* Data used in preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators 
within the ADNI contributed to the design and implementation of ADNI and/or provided 
data but did not participate in analysis or writing of this report. A complete listing of ADNI 
investigators can be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. 
 
† Data used in the preparation of this article was obtained from the Australian Imaging 
Biomarkers and Lifestyle flagship study of ageing (AIBL) funded by the Commonwealth 
Scientific and Industrial Research Organisation (CSIRO) which was made available at the 
ADNI database (www.loni.usc.edu/ADNI). The AIBL researchers contributed data but did not 
participate in analysis or writing of this report. AIBL researchers are listed at 
www.aibl.csiro.au. 
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comprehensively examined, in non-supplemented individuals, serum B12 level associations 
with regional neurodegeneration, hypometabolism, and cognition across the Alzheimer’s 
disease (AD) spectrum, and if B12-related genes influence these relationships.  Serum 
vitamin B12 was assayed from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and 
the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) in individuals 
who were not taking vitamin B12 or multivitamin supplements. The mean age of ADNI 
participants was 74.1 and 52% of participants were male; for AIBL, the mean age was 72.0 
and 47% of participants were male.  Voxel-wise analyses regressed vitamin B12 levels 
against regional gray matter (GM) volume and glucose metabolism (p<.05, family-wise 
corrected). For ADNI GM volumes, there were 39 cognitively normal (CN), 73 mild cognitive 
impairment (MCI), and 31 AD participants.  For ADNI fluorodeoxyglucose PET (FDG-PET) 
images, there were 35 CN, 82 MCI and 34 AD participants.  For AIBL GM volumes, there 
were 311 CN, 59 MCI, and 31 AD participants.  Covariates were age, sex, baseline diagnosis, 
APOE4 status, and BMI.  Single Nucleotide Polymorphisms (SNPs) in MTRR, MTHFR, TCN2, 
and CUBN genes were tested using PLINK and ADNI GWAS data (MAF³0.05, Alpha=.0125, 
corrected). In ADNI participants, higher vitamin B12 negatively predicted GM in the right 
precuneus, left middle and right inferior frontal gyri. In AIBL participants, higher vitamin B12 
was associated with more grey matter in the right amygdala and right superior temporal 
pole.  Higher B12 was related to less FDG metabolism in the right calcarine and precuneus.  
CUBN gene SNPs modified how B12 was associated with GM and FDG. Our findings provide 
evidence that higher B12 and related genotypes in an older population are associated with 
AD neuropathology.  
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Introduction 
 Deficient levels of vitamin B12 or folate lead to increased levels of homocysteine, 
which is a risk factor for thrombosis, microbleeds, strokes, cognitive impairment and 
neuronal atrophy(1; 2). Vitamin B12, or cobalamin, normally contributes to the production of 
myelin in the central nervous system and fatty acid metabolism. When vitamin B12 is 
consumed, it first binds to haptocorrin (or transcobalamin I) to protect the B12 from 
stomach acid.  Intrinsic factor is produced in the stomach and binds to vitamin B12 in the 
intestines to allow absorption into the ileum enterocytes via the membrane protein 
cubilin(3; 4).  Importantly, vitamin B12 is transported to the liver via transcobalamin II, where 
it takes place in folate/B12 dependent remethylation to facilitate the conversion of 
homocysteine to methionine and the subsequent methylation of DNA, proteins and lipids(5).   
The literature is currently mixed about the role of vitamin B12 in brain health. On 
the one hand, vitamin B12 is significantly lower in both plasma(6) and CSF(7) of patients with 
Alzheimer’s disease (AD) versus normally aging controls, suggesting that supplementation 
may be useful. Indeed, clinical trials have found that B12 supplementation may slow brain 
atrophy in Mild Cognitive Impairment, or MCI, that is considered the precursor to AD, when 
Omega-3 fatty acid levels are sufficiently high, perhaps by changing homocysteine levels(8; 9). 
However, vitamin B12 supplementation in aged, cognitively normal adults with diabetes led 
to less grey matter volume in the left middle temporal pole and the left insula(10). In 
addition, aged adults with mildly elevated plasma homocysteine levels showed less total 
brain volume after 2 years of daily supplementation with 500 µg of vitamin B12 and 400 µg 
of folic acid versus placebo tablet(11).  Apolipoprotein E4 (APOE4) carrier status, the 
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strongest genetic risk factor for developing AD, may modify the positive associations 
between B12 and regional GM(12).  
For cognitive function, the literature is also mixed regarding B12 supplementation 
efficacy or its use as a biomarker to track AD-related cognitive decline. Despite 
controversy(13) surrounding the meta-analysis by Clarke et al.(14) in selecting rigorous clinical 
trials and sensitive global cognitive measures in normal aging, meta-analyses indicate that 
vitamin B12 supplementation may not influence cognitive decline among cognitively normal 
(CN) aged adults with type 2 diabetes(14), perhaps due to the mild nature of cognitive 
decline in normal aging and difficulty in controlling for nutritional status(15). Vitamin B12 
combined with folate does appear to have modest clinical efficacy in CN or MCI participants, 
however(16). Qin and colleagues found that individuals in the top quintile for B12 intake 
showed increased performance in working memory, but no differences in memory or 
executive function tests(17).  Conversely, in a study following 765 individuals aged 85 and 
older over 5 years, participants who died or were unable to complete cognitive testing had 
significantly higher plasma vitamin B12 at baseline(18).   
Wide variability in vitamin B12 associations with GM atrophy may be due to vascular 
and/or genetic methylation factors. Thus, it also worthwhile to see if genetic variation in 
vitamin B12 may explain conflicting findings for GM volume, as well as a lack of association 
between vitamin B12 and fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)(19; 
20).  We examined Single Nucleotide Polymorphisms (SNPs) among four a priori selected 
genes involved in B12 transport, uptake, and metabolism, CUBN, MTHFR, MTRR and 
TCN2(21). We therefore systematically investigated associations between circulating B12, 
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regional GM and FDG metabolism, and genotypic variation related to B12-neural 
associations across the AD spectrum in two large cohorts spanning North America and 
Australia.  
Methods 
Participants 
 Data from aged adults were obtained from the ADNI database 
(http://adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, 
led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), 
other biological markers, and clinical and neuropsychological assessment can be combined 
to measure the progression of MCI and early AD. For up-to-date information, see 
http://www.adni-info.org. Written informed consent was obtained from all ADNI 
participants at their respective ADNI sites. The ADNI protocol was approved by site-specific 
institutional review boards. Data was collected by the AIBL study group. AIBL study 
methodology has been reported previously(22).  To eliminate the influence of supplements, 
especially in participants who were receiving increased care from physicians, only 
participants who did not report taking vitamin B12 supplements or multivitamins were 
included in these analyses. 
Serum Biomarkers 
 Vitamin B12 data were downloaded at baseline.  ADNI B12 levels are reported in 
pg/mL and AIBL levels are reported in pmol/L.  All AIBL B12 values were converted to pg/mL 
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for consistency.   Homocysteine was obtained through the ADNI and a data request from 
AIBL.   
APOE Genotype 
 The ADNI Biomarker Core at the University of Pennsylvania conducted APOE ε4 
genotyping. We characterized participants as having zero APOE4 alleles, one APOE4 allele, 
or two APOE ε4 alleles. APOE genotypic data was downloaded for AIBL participants from the 
AIBL.   
Amyloid and Tau CSF Biomarkers 
 CSF sample collection, processing, and quality control of p-tau, total tau, and Aβ1-42 
are described in the ADNI1 protocol manual (http://adni.loni.usc.edu/) and Shaw et al (23).  
Amyloid and tau markers were only available in a very small subset of AIBL participants, so 
these were not assessed. 
Neuropsychological Assessment 
 ADNI utilizes an extensive battery of assessments to examine cognitive functioning 
with particular emphasis on domains relevant to AD. A full description is available at 
http://www.adni-info.org/Scientists/CognitiveTesting.aspx. All subjects underwent clinical 
and neuropsychological assessment at the time of scan acquisition. Neuropsychological 
assessments included: The Clinical Dementia Rating sum of boxes (CDR-sob), Mini-Mental 
Status Exam (MMSE), Auditory Verbal Learning Test (RAVLT), and AD Assessment Schedule - 
Cognition (ADAS-Cog). A composite memory score encompassing the RAVLT, ADAS-COG, 
MMSE, and Logical Memory assessments was also utilized(24).  Additionally, a composite 
executive function score comprising Category Fluency—animals, Category Fluency—
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vegetables, Trails A and B, Digit span backwards, WAIS-R Digit Symbol Substitution, Number 
Cancellation and 5 Clock Drawing items was used(25).  These composite scores were used in 
formal analyses to represent memory and executive function among subjects.  Out of the 
cognitive tests that were available for ADNI, only Logical Memory- Immediate Recall, Logical 
Memory- Delayed Recall, MMSE, and Global CDR scores were available for AIBL, although 
the same protocols were used. An executive function composite factor was available for 
AIBL, although it was comprised of CDR-sob, the Stroop test, the FAS test and Category 
Switch Total(26). 
Magnetic Resonance Imaging (MRI) Acquisition and Pre-Processing 
MRI scans were available for both ADNI and AIBL.  T1-weighted MRI scans were 
acquired within 10-14 days of the screening visit following a back-to-back 3D magnetization 
prepared rapid gradient echo (MP-RAGE) scanning protocol described elsewhere(27). Images 
were pre-processed using techniques previously described(28). Briefly, the SPM12 “New 
Segmentation” tool was used to extract modulated GM and WM volume maps to Montreal 
Neurological Institute (MNI) space. Maps were smoothed with an 8mm Gaussian kernel and 
then used for voxel-wise analyses.  
FDG-PET 
FDG-PET images were available only for ADNI. FDG-PET acquisition and pre-
processing details have been described previously(27). Briefly, 185 MBq of [18-153-F]-FDG 
was injected intravenously. After 30 minutes, six 5-minute frames were acquired. Frames of 
each baseline image series were co-registered to the first frame and combined into dynamic 
image sets. Each set was averaged, reoriented to a standard 160 x 160 x 96 voxel spatial 
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matrix of resliced 1.5 mm3 voxels, normalized for intensity, and smoothed with an 8mm 
FWHM kernel. In order to derive the standardized uptake value ratio (SUVR), pixel intensity 
was normalized according to the pons since it demonstrates preserved glucose metabolism 
in AD(29). Normalization to the pons removed inter-individual tracer metabolism variability. 
The MNI template space was used to spatially normalize images using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/).  
Genomic Data Processing and Quality Control 
Genomic data was only available from ADNI.  Quality control of this data was 
conducted by analyzing Hardy-Weinberg equilibrium (HWE) accepted data for Mendelian 
inheritance errors. From the entire dataset, SNPs were selected for further analyses based 
on HWE P-value > 0.00001, MAF >0.05%, call rate 95%. Samples with greater than 5% 
missingness were removed. Sample genotypes were imputed using 1000Genomes data with 
Shapeit/Impute2 software following the protocol described previously(30). SNPs with call 
rates <95 % or R2 ≤ 0.3 were also excluded, leaving 2,976,223 imputed and genotyped SNPs 
after quality control.  
Statistical Analysis 
For voxel-wise analysis, 2nd-level linear mixed models in SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/) tested main effects of vitamin B12 on 
regional GM volume and FDG, controlling for age, sex, BMI, baseline diagnosis, APOE4 
status. Follow-up voxel-wise analyses were conducted on each diagnostic group, separately.  
The thresholds were set at p < .005 (uncorrected) and P < .05 (corrected) for voxels and 
clusters respectively. Results were considered significant at the cluster level. As described 
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previously(31), in order to reduce type 1 error, we utilized a GM threshold of 0.2 to ensure 
that voxels with <20% likelihood of being GM were not analyzed. For GM, Monte Carlo 
simulations in ClusterSim (http://afni.nimh.nih.gov/afni/doc/manual/3dClustSim) were used 
to estimate that 462 contiguous voxels were needed for such a cluster to occur at p < 0.05. 
For FDG voxel-wise analyses, Monte Carlo simulations in ClusterSim were used to estimate 
that 224 contiguous voxels were needed for such a cluster to occur at p < 0.05.  
All genetic association analyses were conducted using PLINK v1.9 (http:// www.cog-
genomics.org/plink2).  The following genes were analyzed through linear associations in 
Caucasian participants with a phenotype of the predicted GM and FDG uptake in maximal 
voxels from voxel-wise analyses: CUBN, MTHFR, MTRR and TCN2.  Covariates for PLINK 
analyses included sex, clinical diagnosis, intracranial volume, and APOE4 status. A Holm-
Bonferroni threshold for significance was set of .05/4, p < 0.0125(32).  
Non-voxel linear mixed regression was conducted using SPSS 25 (IBM Corp., Armonk, 
NY) to test the main effects and interactions with diagnosis and APOE4 status of vitamin 
B12 on cognitive scores and biomarkers.  Binomial logistic regression was also used to 
assess the odds ratio of a given participant being diagnosed as MCI or AD versus the CN 
reference group.  Covariates included age, sex, BMI, baseline diagnosis and APOE4 status.  
Years of education was also added as a covariate in models with cognitive scores. 
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 Results 
Demographics and Data Summary 
 Clinical and demographic data for subjects are presented in Table 6.1a, for both 
ADNI and AIBL participants.  Vitamin B12 was converted to pg/mL.  A sub-sample of 
participants had FDG data, where clinical and demographic data are listed in Table 6.1b. 
Regional Grey Matter Volume 
Voxel-wise analysis was used to regress plasma vitamin B12 against regional GM at 
baseline for 144 participants from ADNI and 401 participants from AIBL, who had structural 
GM MRI scans as well as demographic and biological data.  For ADNI participants, higher 
plasma vitamin B12 was correlated with less GM in three significant clusters.  The most 
significant cluster consisted of 507 voxels which was primarily in the right precuneus (Figure 
6.1) and right posterior cingulate gyrus.  The other clusters spanned the left middle frontal 
gyrus and right inferior frontal gyrus.  See Table 6.2 for a full listing of significant clusters.  
When examining each diagnostic group separately, only the MCI participants showed 
significant associations for B12 and GM.  Higher B12 was associated with less GM in the 
right thalamus (k=1023).  For AIBL participants, higher plasma vitamin B12 was correlated 
with more grey matter (k=559) in the right amygdala and right superior temporal pole.  See 
Table 6.3 for a full listing of significant clusters.  When examining each diagnostic group 
separately, only the cognitively normal participants showed significant associations, with 
more B12 associated with more grey matter in three significant clusters, one in the right 
superior frontal gyrus (k=1186), one in the right precuneus (k=2105), and one in the right 
supplementary motor area (k=496).   
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Regional FDG Metabolism 
FDG data was only available for ADNI participants. Voxel-wise analysis was similarly 
used to regress plasma B12 concentrations against FDG glucose uptake in 151 ADNI 
participants. Higher plasma vitamin B12 was correlated with less FDG glucose uptake in the 
right calcarine and right precuneus, where Figure 6.2 illustrates the relationship at the 
maximum voxel in the right calcarine (24, -48, 6) (Figure 6.2).  See Table 6.4 for a full listing 
of significant clusters.  When splitting the analyses by baseline diagnosis group, no clusters 
survived correction for CN and AD participants.  For MCI participants, there were both 
negative and positive associations with vitamin B12.  Higher vitamin B12 was associated 
with less grey matter in one large cluster (k=2166) spanning the right lingual gyrus and the 
right thalamus.  In contrast, higher vitamin B12 was associated with more grey matter in 
four smaller clusters, spanning the left inferior frontal gyrus (k=780), right crus 1 of the 
cerebellum (k=841 and 275), and the right inferior frontal gyrus (k=615).   
Genotype Analyses for Vitamin B12 and Predicted Differences in GM and FDG 
SNPs for genes associated with vitamin B12 uptake, transport, and metabolism were 
next used as predictors of interest, to see if genotypes might explain the wide variance seen 
in B12 associations. Linear regression in PLINK tested the additive genetic model of each 
SNP for associations with GM and FDG predicted values, from the voxel-wise analyses 
reported above.  Nine SNPs in the CUBN gene were significantly associated with GM and 
passed Holm-Bonferroni correction, seven which were detrimental for individuals who had 
the minor allele and two which were beneficial (Table 6.5).  One SNP, rs7918972 in the 
CUBN gene was significantly associated with FDG and passed Holm-Bonferroni correction, 
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which was associated with less FDG uptake (β=-0.094, p=0.0065). MTHFR, MTRR, and TCN2 
SNPs were not significantly associated with GM or FDG B12 predicted values. 
Cognition and Biomarkers 
Vitamin B12 was not significantly correlated with CD Global scores, CDR-SOB 11, 
MMSE, composite executive factors, or the composite memory factor for ADNI or AIBL 
participants.  There was a significant Baseline Diagnosis * B12 interaction for predicting the 
RAVLT learning score for ADNI participants (F=3.080, p=0.048). Individually, higher B12 was 
associated with better scores in AD (β =0.0027±0.001, p=.042) but trending worse scores in 
MCI (β =-0.0022±0.001, p=.061).  
For biomarkers, higher vitamin B12 was associated with lower plasma homocysteine 
levels in ADNI participants (b±SE=-.0034±0.001, p=0.001) and AIBL participants (b±SE=-
0.0021±0.001, p<.001).  There were no significant associations between vitamin B12 and 
CSF total tau, p-tau-181 or Aβ1-42 for ADNI participants.  Only a very small subset of AIBL 
participants had available CSF data, so these associations were not assessed. 
Baseline Diagnosis: Differences in Vitamin B12 Levels 
 Binary and multinomial logistic regression were used to examine if plasma vitamin 
B12 levels predicted an increased likelihood of being MCI or AD. The reference group was 
CN. Serum vitamin B12 levels did not predict a higher Odds Ratio for being MCI or AD. 
Discussion 
 We hypothesized that serum vitamin B12 levels may be a useful biomarker for AD-
related brain atrophy, hypometabolism, and cognitive decline.  We originally predicted that 
there would be an inverse correlation between higher serum vitamin B12 levels and lower 
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markers of AD, due to previous work from other groups(33; 34).  This hypothesis was true for 
AIBL participants, where higher vitamin B12 was related to more grey matter in the right 
amygdala and right superior temporal pole. Strikingly, in ADNI participants, higher serum 
vitamin B12 was instead related to less grey matter volume in the right precuneus, left 
middle and right inferior frontal gyri and less FDG metabolism in areas spanning the right 
calcarine and precuneus, areas which are adversely affected in AD. A possibility for these 
negative findings is that vitamin B12 is not necessarily a negative modifier of GM or FDG 
uptake.  Instead, raised levels above an individuals’ historical average may indicate ongoing 
systemic or neurological damage. Mosconi and colleagues did not find any correlation 
between vitamin B12 intake and FDG associations, although plasma vitamin B12 levels have 
been shown to be correlated with increased all-cause mortality in women aged 85 or 
greater(35).  Also, individuals with hyperlipidemia and non-insulin-dependent diabetes had 
significantly higher levels of vitamin B12 compared to healthy controls(36).  Additionally, 
higher serum vitamin B12 may be a sign of its decreased cellular uptake.  Vascular damage 
is a common feature of AD(37), and the vascular endothelium via the CD320 receptor may 
mediate the homeostasis between the serum and tissue homeostasis of vitamin B12(38). 
Finally, disease status may also modify uptake and metabolism dynamics of B12. For 
example, higher serum B12 was related to better memory performance in CN, but worse in 
MCI. This may be why we saw the positive relationship with GM in AIBL participants, 
because the distribution was strongly skewed towards CN participants.  It is unclear what 
mechanisms might underlie these differences in either B12 transport, utilization, or 
metabolism. 
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 Supplementation with B12 in individuals with dementia has been inconclusive.  
There was no significant improvement in memory or cognition in individuals with dementia 
who had low levels of vitamin B12 and were subsequently supplemented, however the 
supplemented individuals showed better verbal fluency scores compared to non-
supplemented controls (39).  However, the VITACOG trial showed that B-vitamin 
supplementation was related to positive cognitive outcomes in individuals in the top tertile 
of baseline omega-3 fatty acids, compared to individuals with lower baseline omega-3 fatty 
acid levels, perhaps due to a synergistic effect on phospholipid production for the brain(40). 
It has also been shown that vegetarians, though unlikely to be classified as clinically 
deficient, are more likely to have low-normal levels of vitamin B12(41).  This could likely be 
extended to individuals who consume plants as a larger portion of their meals, compared to 
meat.  Perhaps vitamin B12 status may act as an indicator of the ratio of meat intake to 
plant intake in the diet, and this may manifest in predicting AD outcomes, which have also 
been linked to plant-based dietary habits(42).  The high intake of methionine in meat-heavy 
diets may provide an additional explanation. In a group of APOE deficient mice, mice that 
were fed a high methionine diet with high levels of B-vitamins showed significantly greater 
aortic plaques compared to mice that were fed a B-vitamin deficient diet, even though the 
first group had normal levels of homocysteine and the second group had high levels(43). It is 
still puzzling that we still see an inverse correlation between serum vitamin B12 and 
homocysteine levels, even though higher B12 is correlated with worse neural outcomes.  
Potentially, vitamin B12 still is taken up by the liver in individuals with higher serum vitamin 
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B12, but their high B12 levels may be indicative of other tissues, such as the brain, being 
unable to transport B12 or utilize it properly. 
Alternatively, genetic polymorphisms in B vitamin uptake, transport, and 
metabolism may modify how B12 is utilized, and affect B12 levels themselves. We found 
that minor allele polymorphisms in the CUBN gene tracked the association between high 
B12 and less regional GM.  Cubulin is also an apolipoprotein receptor, and is involved in the 
absorption of high density lipoproteins in the kidney(44). Perhaps cubulin polymorphisms 
may lead to decreased apolipoprotein reuptake in the kidneys, which may put a patient at 
risk for dementia.  
There are several limitations of the study. First, only vitamin B12 was measured in 
the participants.  Ideally, holotranscobalamin and methylmalonic acid would also be 
measured, which would indicate the level of vitamin B12 available for cellular uptake, and 
the absence of vitamin B12 from necessary methylation reactions, respectively(45). Current 
practice in the healthcare field is to test serum vitamin B12 levels or holotranscobalamin 
first (if a patient has risk factors for vitamin B12 deficiency); a serum vitamin B12 level of 
less than 200 pg/mL is considered deficient (46).  Subsequently, current practice is for 
practitioners to test an additional metabolic indicator, either methyl malonic acid or 
homocysteine (47). Second, it is difficult to determine the players involved in an individual’s 
vitamin B12 levels.  This can be impacted by proton pump inhibitors(48), level of animal 
product intake(49), genetic variability(21) as we too have illustrated. Perhaps the interaction 
between vitamin B12 and one or more of these variables may play a role in cognitive 
decline.  We were also unable to assess associations with physical activity, circulating 
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vitamin B12, and neurological outcomes.  Additionally, a limitation of the study is the lack of 
FDG scans and genetic data from AIBL.  Lastly, because the overwhelming majority of ADNI 
participants are of Caucasian descent, we were only able to reliably test the interactions 
between genetic data and volumetric/function brain outcomes in those individuals. It would 
be worthwhile to determine if similar genes are implicated in an African-American cohort, 
as the incidence of AD is much higher among African-Americans compared to Caucasians(50). 
Conclusion 
This study is the first, to our knowledge, to show a negative correlation between 
serum vitamin B12 and brain volume and FDG metabolism across the AD spectrum. This 
result was unexpected, given previous B-vitamin supplementation trials showing less 
hippocampal atrophy(9). Additionally, we have shown that these results may be influenced 
by genetic mutations related to vitamin B12 uptake and metabolism in the liver.  Future 
research should focus on the rate of uptake of vitamin B12 into healthy and diseased 
neuronal cells and determine if therapeutic methods exist for improving vitamin B12 
utilization in the AD population. 
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Tables and Figures 
 
Table 6.1a Demographics for ADNI and AIBL participants with GM images 
 ADNI CN=39 MCI=73 AD=31 
Age 74.00 ± 5.17 73.16 ± 7.24 73.58 ± 6.19 
Serum B12 (pg/mL) 439.67 ± 213.00 382.63 ± 149.22 420.51 ± 238.41 
BMI 26.61 ± 4.04 25.42 ± 3.68 25.14 ± 3.90 
Sex % Female 51.3% 41.4% 61.3% 
% APOE 4 carriers*** 25.6% 61.7% 74.2% 
AIBL CN=311 MCI=59 AD=31 
Age*** 71.17 ± 6.49 75.37 ± 7.25 73.23 ± 8.31 
Serum B12 (pg/mL) 415.55 ± 163.63 429.70 ± 156.91 405.21 ± 181.82 
BMI 26.29 ± 3.94 26.31 ± 4.54 25.86 ± 3.89 
Sex % Female** 56.6% 35.6% 45.2% 
% APOE 4 carriers*** 29.9% 47.5% 67.7% 
 
Values are mean ± SD. *,**,***=p<.05, .01, .001. Chi-square analyses were conducted to 
examine differences between gender and APOE4 status. ANOVA was otherwise used. 
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Table 6.1b Demographics for ADNI Participants with FDG Images 
 ADNI CN=35 MCI=82 AD=34 
Age* 77.03 ± 5.05 73.54 ± 7.06 74.04 ± 7.35 
Serum B12 (pg/mL) 407.40 ± 193.42 397.24 ± 181.08 467.71 ± 189.29 
BMI* 27.27 ± 3.64 26.75 ± 4.39 74.04 ± 7.35 
Sex % Female 40% 32.9% 47.1% 
% APOE 4 carriers*** 17.2% 62.2% 70.6% 
 
Values are mean ± SD. *,**,***=p<.05, .01, .001. Chi-square analyses were conducted to 
examine differences between gender and APOE4 status. ANOVA was otherwise used. 
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Table 6.2 Regional associations of higher serum vitamin B12 and less grey matter volume in 
ADNI participants 
 
Location T value X, Y, Z Cluster size (voxels) 
Precuneus (R) 4.21 10, -54, 27 507 
Posterior cingulate gyrus (R) 3.17 8, -46, 22  
Precuneus (R) 2.70 14, -62, 33  
Middle frontal gyrus (R) 3.92 -24, 51, 6 754 
Middle frontal gyrus (L) 3.35 -24, 24, 39  
Middle frontal gyrus (L) 3.24 -38, 48, 20  
Middle frontal gyrus (R) 3.85 26, 51, 3 2453 
Inferior frontal gyrus (R) 3.75 44, 39, 27  
Inferior frontal gyrus (R) 3.62 51, 32, 8  
 
This table depicts regions where all subjects had less predicted gray matter volume per unit 
increase in vitamin B12. The highest t value for a given cluster of significant, contiguous 
voxels is shown. For clusters that extended over more than 15 mm, the highest t value in 
those areas is indicated. 
Coordinates are in MNI atlas space. Brains are oriented in neurological space. 
 
L left hemisphere, R right hemisphere 
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Table 6.3 Regional associations of higher serum vitamin B12 and more grey matter volume 
in AIBL participants 
 
Location T value X, Y, Z Cluster size (voxels) 
Amygdala (R) 3.57 30, 4, -24 559 
Superior temporal pole (R) 3.13 45, 14, -18  
 
 
This table depicts regions where all subjects had more predicted gray matter volume per 
unit increase in vitamin B12. The highest t value for a given cluster of significant, contiguous 
voxels is shown. For clusters that extended over more than 15 mm, the highest t value in 
those areas is indicated. 
Coordinates are in MNI atlas space. Brains are oriented in neurological space. 
 
L left hemisphere, R right hemisphere 
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Table 6.4 Regional associations of higher serum vitamin B12 and less FDG glucose uptake 
 
Location T value X, Y, Z Cluster size (voxels) 
Calcarine (R) 3.90 24, -48, 6 479 
Precuneus (R) 3.67 14, -40, 4  
Thalamus (R) 4.40 10, -32, 10  
 
This table depicts regions where all subjects had less predicted FDG glucose uptake per unit 
increase in vitamin B12. The highest t value for a given cluster of significant, contiguous 
voxels is shown. For clusters that extended over more than 15 mm, the highest t value in 
those areas is indicated. 
Coordinates are in MNI atlas space. Brains are oriented in neurological space.   
 
L left hemisphere, R right hemisphere 
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Table 6.5 Association between CUBN SNPs and predicted GM at the maximal voxel in the 
right precuneus  
 
Chromosome SNP BP A1 N Beta F Statistic P value  
10 rs10904831 16931344 T 111 -0.08162 -2.542 0.01249 
10 rs2356587 16979380 C 111 0.02488 2.594 0.01085 
10 rs1801234 16979661 C 111 0.02488 2.594 0.01085 
10 rs7072262 17057766 T 109 -0.02607 -2.741 0.007229 
10 rs4614335 17059826 A 108 -0.0262 -2.74 0.007252 
10 rs12218279 17060676 A 109 -0.02607 -2.741 0.007229 
10 rs7897550 17064992 A 111 -0.02482 -2.636 0.009651 
10 rs11254331 17065357 A 110 -0.02465 -2.612 0.01035 
10 rs17139621 17065761 C 110 -0.02465 -2.612 0.01035 
 
Beta values represent the difference in the predicted value of grey matter with an increase 
from no risk allele to one risk allele or two risk alleles.  BP= base pair location of SNP; A1= 
minor allele. 
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Figure 6.1 Brain areas showing less GM corresponding to increased vitamin B12.  The graph 
depicts the relationship at a maximal voxel in the right precuneus.  
 
 156 
 
 
Figure 6.2 Brain areas showing less FDG metabolism corresponding to increased vitamin 
B12.  The graph depicts the relationship at a maximal voxel in the right calcarine.  
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Abstract 
 Higher serum vitamin B12 has been shown to be related to improved cognition in 
cognitively unimpaired adults in middle to late age.   However, relatively few studies have 
examined the relationship between vitamin B12 and cognition in younger adults, especially 
with a focus on executive function.  Sixty healthy young adults were recruited across the 
BMI groups of lean (BMI of 18.5-24.9) and obese (BMI ³30).  Participants underwent a 
fasting blood draw and a battery of executive function related cognitive tests including the 
California Verbal Learning Test, EXAMINER battery, The Trail Making Test parts A and B and 
Wechsler Adult Intelligence- Scale Revised Digit Span test.  A MANCOVA encompassing all of 
the digit span variables showed a significant effect of vitamin B12, while follow-up linear 
mixed models showed that individually, vitamin B12 modulated the digit span forward 
score, while covarying for age and BMI.  This provides evidence that vitamin B12 may be 
involved in the execution of higher-order tasks. 
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Introduction 
 Vitamin B12, also known as cobalamin, is a water-soluble vitamin mostly derived 
from animal sources (1).   A required cofactor for methionine synthase, vitamin B12 aids in 
the regeneration of methionine from homocysteine, which takes place mostly in the liver (2).  
Additionally, vitamin B12 is necessary for red blood cell formation, DNA synthesis, and the 
production of myelin in the central nervous system (1).  Vitamin B12 is able to cross the 
blood brain barrier in a selective manner (3). 
 When vitamin B12 is consumed, it is released from bound proteins in the stomach’s 
acidic environment (4).  Intrinsic factor, which is produced in the parietal cells of the 
stomach, bind to vitamin B12 to transport it to its absorption site in the ileum enterocytes 
(4).  In the plasma, vitamin B12 travels either bound to haptocorrin or transcobalamin (called 
holotranscobalamin) (4).  Holotranscobalamin is the biologically available form of vitamin 
B12 which can be readily accessed by the cells, while vitamin B12 bound to haptocorrin is 
only available to the liver (4).  Risk of vitamin B12 deficiency is typically seriously considered 
when an individual shows serum vitamin B12 (reflective of holotranscobalamin) levels 
below approximately 200 pg/mL, however methylmalonic acid levels above 0.4 micromol/L 
may be a more sensitive indicator of vitamin B12 deficiency, because this is a barometer of 
the functional ability of vitamin B12 (1).  Causes of vitamin B12 deficiency include: 
vegetarianism/veganism, gastrectomy, malabsorption disorders and genetic polymorphisms 
(5). 
 The vast majority of research in the realm of vitamin B12 and cognition has utilized 
an older population, and there is a lack of information regarding the impact of serum 
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vitamin B12 on cognition in young, healthy adults.  In a supplementation study with 
cognitively unimpaired individuals aged 70 or older with mild vitamin B12 deficiency, 195 
participants were randomized between three groups: 1000 µg vitamin B12, 1000 µg vitamin 
B12 and 400 µg folic acid, or placebo for 24 weeks (6).  Individuals who were in the vitamin 
B12 supplement only group performed worse on memory tests at outcome visit compared 
to the placebo group, overall; additionally, there was no significant difference with respect 
to executive function or sensomotor speed between treatment groups (6).  However, in 
another study of cognitively normal adults, participants with low levels of vitamin B12 
showed poorer scores on the block design test, an examination of spatial visualization, and 
letter fluency test (7).  In a cohort of individuals with HIV (mean age 51), low levels of vitamin 
B12 were associated with decreased scores on the Trail Making Part B test and WAIS digit 
span test for executive function as well as worse scores on the Peg Board Test for 
psychomotor processing (8).  Additionally, in a cohort of cognitively unimpaired older adults, 
serum methylmalonic acid was related to worse global cognitive scores, worse episodic 
memory and worse perceptual speed (9).  In a population of healthy individuals aged 60 or 
older, participants in the bottom 5% of serum vitamin B12 levels scored significantly worse 
on the Halstead-Reitan test for abstract thinking as well as on the Weschler Memory Test, 
however this relationship was not seen when assessing vitamin B12 through weighed 3-day 
food diaries (10).  Lastly, the genetic polymorphism apolipoprotein e4 (APOE e4) may 
modulate the effect of vitamin B12 on memory, where vitamin B12 is beneficial in non-
carriers but not in carriers (11).  The purpose of this study was to determine if differences 
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exist in the younger adult population with respect to serum vitamin B12 and performance 
on cognitive tests. 
Methods 
Participants 
 Participants were a part of the Obesity, Signal Imaging, and Reactions at Iowa State 
(OSIRIS) study with a primary object of determining the effect of adiposity and related 
biomarkers on brain function using electroencephalography and cognitive tests.  A 
secondary outcome for this study was to determine the impact of vitamin B12 on 
performance in cognitive tests.  Subjects were recruited who met the following criteria: 
18-40 years of age; lean (BMI of 18.5-24.9) or obese (BMI of 30 or above); no history of 
cardiovascular disease, hypertension, or diabetes; not currently taking weight reduction 
medication; non-smoking; and no history of major psychiatric disorders.  The study ran 
between June of 2015 and December of 2018.  All participants gave written informed 
consent and all study procedures were approved by the Institutional Review Board at Iowa 
State University.   
Clinical and Cognitive Procedures 
 Participants underwent a fasting blood draw and samples were sent to Quest 
Diagnostics for assays.  Anthropometrics were obtained as well as subject demographics.  A 
light breakfast was provided and then participants took part in cognitive testing with 
trained research assistants.  Cognitive tests included: the California Verbal Learning Test 
(CVLT), the EXAMINER battery, the Trail Making Test (parts A and B), the Paired Associates 
Test, and the Wechsler Adult Intelligence- Scale Revised Digit Span test. 
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Statistical Analyses 
 All statistical analyses were performed on SPSS 25 (IBM Corp., Armonk, NY).  
Covariates included: age, sex and BMI.  To robustly contain type 1 error, a multivariate 
omnibus was initially conducted on the following categories of cognitive tests: 1. Working 
Memory: Wechsler digit span forward, Wechsler digit span backward, dot counting, 1-back 
and 2-back; and 2. Memory: CVLT learning (trial 5 minus trial 1), CVLT short-delay, CVLT 
long-delay and the Paired Associates Test.  This allows us to determine if there is an overall 
significant association between all cognitive tests, allowing subsequent analyses to 
investigate each individual test without Bonferroni or similar corrections (12).  Follow-up 
analyses were linear mixed models regressing serum vitamin B12 levels against cognitive 
test outcomes. 
Results 
Demographics and Data Summary 
 Summary information is listed in Table 7.1.  There were a total of 34 lean 
participants and 26 participants with obesity.  There were no significant differences 
between groups based on age, sex, or ethnicity (% White).  However, serum vitamin B12 
levels were significantly higher in the lean group compared to the group with obesity.   
Cognitive Test Results 
 The multivariate analysis with working memory variables (digit span forward, digit 
span backwards, dot counting, 1-back and 2-back) showed a significant effect of vitamin B12 
(F=2.76, p=0.030), the effect was positive for each variable that was significant within the 
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multivariate analysis.  The multivariate analysis with memory variables (CVLT learning, CVLT 
short-delay, CVLT long-delay and the Paired Associates Test) was non-significant. 
 For follow-up linear mixed models, there was a significant positive association 
between vitamin B12 and the Weschler digit span forward score (β±SE=0.003 ± 0.001, 
p=0.004) (Figure 7.1).  Linear mixed models for vitamin B12 predicting digit span backwards, 
dot counting, 1-back and 2-back were non-significant.   
Discussion 
 In this study, we found that vitamin B12 had a significant overall effect on working 
memory variables.  In addition, vitamin B12 was significantly associated with the individual 
digit span forward score. These findings are consistent with results from Qin and colleagues, 
who showed that individuals in the top quintile of vitamin B12 intake had significantly 
better scores on the digit symbol substitution test (also tests working memory) (13).   
A potential mechanism could be through increased cerebral blood flow with higher 
levels of B12.  Chambers and colleagues showed that in participants with heart disease, 
participants who were given a 5 mg folic acid and 1 mg vitamin B12 supplement per day for 
8 weeks showed increased brachial artery flow dilation, compared to placebo (14).  Although 
our participants did not have heart disease, a similar mechanism could be taking place. 
 Another potential mechanism could be related to the changes in white matter 
structure of young adults, as measured by fractional anisotropy, that Gupta and others 
noted in participants that were vitamin B12 deficient (15).  Similar results were shown in the 
hippocampus in another study of individuals with vitamin B12 deficiency (16).  Although none 
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of our participants were clinically deficient in vitamin B12, perhaps this could play a role to a 
lesser extent in participants at the low-end of normal vitamin B12 levels.  
 We also found that serum vitamin B12 levels were significantly lower in participants 
with obesity, compared to lean participants.  The difference in vitamin B12 levels between 
lean and obese participants has been shown in previous studies.  The authors postulated 
that the decreased vitamin B12 levels in individuals with obesity could be due to higher 
incidences of GERD, small intestinal bacteria overgrowth, and inflammation, which could 
decrease vitamin B12 absorption (17).  However, further studies are needed to confirm 
causation. 
 Several limitations of the study should be noted.  First, due to budgetary constraints, 
we did not analyze other markers of vitamin B12 status such as homocysteine and 
methylmalonic acid, which would give us further insight into vitamin B12’s functional 
capacity in an individual.  Further, we did not track the dietary intake of the participants, 
which would have given information regarding vitamin B12 intake. 
Conclusion 
 This is the first study to our knowledge to assess the association between serum 
vitamin B12 and cognitive factors in a young, non-vitamin B12 deficient, healthy population.  
Our findings that vitamin B12 levels are associated with improved executive function 
warrant future research into a potential benefit of having higher vitamin B12 status within 
the normal range. 
 
 
  
 164 
References 
1. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary 
Reference Intakes and its Panel on Folate other B Vitamins and Choline (1998) The National 
Academies Collection: Reports funded by National Institutes of Health. In Dietary Reference 
Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, 
Biotin, and Choline. Washington (DC): National Academies Press (US)National Academy of 
Sciences. 
2. O'Leary F, Samman S (2010) Vitamin B12 in health and disease. Nutrients 2, 299-316. 
3. Kidd HM, Gould CE, Thomas JW (1963) Free and total vitamin B12 in cerebrospinal fluid. 
Can Med Assoc J 88, 876-881. 
4. Moll R, Davis B (2017) Iron, vitamin B12 and folate. Medicine 45, 198-203. 
5. Fernández-Bañares F, Monzón H, Forné M (2009) A short review of malabsorption and 
anemia. World journal of gastroenterology 15, 4644-4652. 
6. Eussen SJ, de Groot LC, Joosten LW et al. (2006) Effect of oral vitamin B-12 with or 
without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a 
randomized, placebo-controlled trial. The American Journal of Clinical Nutrition 84, 361-370. 
7. Wahlin A, Hill RD, Winblad B et al. (1996) Effects of serum vitamin B12 and folate status 
on episodic memory performance in very old age: a population-based study. Psychol Aging 
11, 487-496. 
8. Falasca K, Di Nicola M, Di Martino G et al. (2019) The impact of homocysteine, B(12), and 
D vitamins levels on functional neurocognitive performance in HIV-positive subjects. BMC 
infectious diseases 19, 105-105. 
9. Tangney CC, Aggarwal NT, Li H et al. (2011) Vitamin B12, cognition, and brain MRI 
measures: a cross-sectional examination. Neurology 77, 1276-1282. 
10. Goodwin JS, Goodwin JM, Garry PJ (1983) Association between nutritional status and 
cognitive functioning in a healthy elderly population. Jama 249, 2917-2921. 
11. Vogiatzoglou A, Smith AD, Nurk E et al. (2013) Cognitive function in an elderly 
population: interaction between vitamin B12 status, depression, and apolipoprotein E 
epsilon4: the Hordaland Homocysteine Study. Psychosom Med 75, 20-29. 
 165 
12. Hummel TJ, Sligo JR (1971) Empirical Comparison of Univariate and Multivariate Analysis 
of Variance Procedures. Psychological Bulletin 76, 49-57. 
13. Qin B, Xun P, Jacobs DR, Jr. et al. (2017) Intake of niacin, folate, vitamin B-6, and vitamin 
B-12 through young adulthood and cognitive function in midlife: the Coronary Artery Risk 
Development in Young Adults (CARDIA) study. American journal of clinical nutrition 106, 
1032-1040. 
14. Chambers John C, Ueland Per M, Obeid Omar A et al. (2000) Improved Vascular 
Endothelial Function After Oral B Vitamins. Circulation 102, 2479-2483. 
15. Gupta PK, Gupta RK, Garg RK et al. (2014) DTI correlates of cognition in conventional 
MRI of normal-appearing brain in patients with clinical features of subacute combined 
degeneration and biochemically proven vitamin B(12) deficiency. AJNR Am J Neuroradiol 35, 
872-877. 
16. Tak AZA, Dayan E, Bulut HT (2018) Evaluation of diffusion tensor imaging changes and 
neurocognitive effects of asymptomatic vitamin B12 deficiency. Acta Neurol Belg 118, 289-
296. 
17. Wiebe N, Field CJ, Tonelli M (2018) A systematic review of the vitamin B12, folate and 
homocysteine triad across body mass index. Obesity Reviews 19, 1608-1618. 
 
  
 166 
Tables and Figures 
 
Table 7.1. Subject Demographics 
 
 Lean Participants  
(n=34) 
Participants with Obesity 
(n=26) 
Age 24.06 ± 4.62 26.23 ± 5.50 
Sex (% Female) 50% 61.5% 
BMI (kg/m
2
)*** 22.05 ± 1.96 34.90 ± 6.09 
Ethnicity (% White) 58.8% 80.8% 
Serum Vitamin B12 (pg/mL)* 689.62 ± 315.92 516.16 ± 224.41 
 
Values are mean ± SD. *,**,***=p<.05, .01, .001. Chi-square analyses were conducted to 
examine differences between sex and ethnicity. ANOVA was otherwise used. 
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Figure 7.1 The association between serum vitamin B12 and covariate adjusted digit span 
forward scores. 
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 GENERAL CONCLUSIONS 
 Cognitive decline and AD have been repeatedly linked to diseases such as type 2 
diabetes, hypertension, dyslipidemia, and metabolic syndrome (1; 2; 3).  Metabolic 
dysfunction is also correlated with increased oxidative stress and inflammation, both in the 
brain and throughout the body, which is correlated with the accumulation of amyloid 
plaques and tau tangles (1).  The studies reported in this dissertation add evidence to the 
current body of knowledge that the markers of metabolic dysfunction (autotaxin and 
insulin-like growth factor binding protein 2) correspond with AD outcomes and further 
emphasize the importance of nutrition-related interventions that may improve metabolic 
function and lessen risk of AD or progression of the disease.  Oxidative stress on its own is 
strongly implicated in the structural and functional changes that are seen in the brain in AD.  
Our report of the impact of superoxide dismutase 1 on AD outcomes provide corroboration 
to an overwhelmed antioxidant system in AD that cannot keep up with growing amounts of 
reactive oxygen species.  Another avenue that interventions should investigate is dietary 
approaches to strengthen the body’s antioxidant system, such as increased intake of berries 
and leafy greens, and reduce its workload via lower levels of oxidative stress. 
In addition, high levels of serum homocysteine have been associated with both 
cardiovascular disease and AD in many studies (4; 5).  Mechanisms that have been suggested 
include: excessive excitation of neurons and neuronal death, oxidative stress, damage to 
the vasculature, DNA damage, and the initiation of formation of amyloid and tau proteins 
(6).  Because vitamin B12 is highly involved in maintaining low homocysteine levels, it has 
been hypothesized that vitamin B12 may be protective of AD (7).  However, our findings 
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related to vitamin B12 and neurologic outcomes are conflicting.  While serum vitamin B12 
levels were related to improved cognition in younger adults, the relationship was largely 
deleterious in older adults across the AD spectrum.  While it is our suspicion that vitamin 
B12 levels may be reflecting systemic issues or decreased cellular uptake and not causative 
of AD pathology, clearly more research is needed in this area and vitamin B12 supplements 
should be cautioned in the older population that is not deficient.   
Although a pessimistic view of AD research outcomes is commonly held due to 
modest improvements in current practice and pharmacologic treatments available, there is 
promise for nutritional modifications in slowing or halting disease progression (8; 9).  In 
addition, each biomarker that is identified can aid in accurately noting preclinical changes so 
patients have the opportunity to make dietary and lifestyle changes, such as increasing 
physical activity to decrease IR, that may change their neurological trajectory.  
Multidisciplinary teams that include physicians, registered dietitians, physician assistants 
and nurse practitioners, nurses, socials workers, and other important health care 
professionals are crucial in these interventions and these groups are the leaders of progress 
in AD research. 
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